

 



<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
  "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml"
      xmlns:foaf="http://xmlns.com/foaf/0.1/"
      xmlns:dc="http://purl.org/dc/terms/"
      xmlns:doi="http://dx.doi.org/"
      xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
      xmlns:xsd="http://www.w3.org/2001/XMLSchema-datatypes#"
      lang="en" xml:lang="en"
      itemscope itemtype="http://schema.org/Article"
      class="no-js">
<head prefix="og: http://ogp.me/ns#">
  <title>PLOS ONE: Patient and Regimen Characteristics Associated with Self-Reported Nonadherence to Antiretroviral Therapy</title>


<link rel="stylesheet" type="text/css"  href="/css/global-min.css?v=izteQ6tu7kgsJZW_xmrYizvKiHM" />


    <!--[if lte IE 7]>
<link rel="stylesheet" type="text/css"  href="/css/lte_ie7-min.css?v=3bykQUyQmReeuobVyPozcJ9LxRc" />
    <![endif]-->


<link rel="stylesheet" type="text/css"  href="/css/jquery-ui-min.css?v=eXDHTEJM0lIAmDe5k0I0Ad4nxNo" />


<link rel="stylesheet" type="text/css"  href="/css/journal.css?v=T7ZVxJfgk9jNxLAJ2qHz1vZpgYU" />


<link rel="stylesheet" type="text/css" media="print" href="/css/print-min.css?v=T5lb0B3q6EXBsuDluc5V5w+AkRc" />


  <link rel="stylesheet" href="http://f.fontdeck.com/s/css/js/www.plosone.org/24557.css" type="text/css"/>

  <!--chartbeat -->
  <script type="text/javascript">var _sf_startpt = (new Date()).getTime()</script>
  <script>document.documentElement.className += ' js';</script>

  <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
  <meta http-equiv="X-UA-Compatible" content="IE=EmulateIE7; IE=EmulateIE9"/>
  <meta name="description" content="PLOS ONE: an inclusive, peer-reviewed, open-access resource from the PUBLIC LIBRARY OF SCIENCE. Reports of well-performed scientific studies from all disciplines freely available to the whole world."/>
  <meta name="keywords" content="PLOS, Public Library of Science, Open Access, Open-Access, Science, Medicine, Biology, Research, Peer-review, Inclusive, Interdisciplinary, Ante-disciplinary, Physics, Chemistry, Engineering"/>
  <meta name="almHost" content="http://alm.plos.org/api/v3/articles"/>
  <meta name="searchHost" content="http://api.plos.org/search" />
  <meta name="termsHost" content="http://api.plos.org/terms" />
  <meta name="solrApiKey" content="plos"/>
  <meta name="almAPIKey" content="3pezRBRXdyzYW6ztfwft" />
  <meta name="currentJournal" content="PLoSONE" />
  <meta name="almRequestBatchSize" content="" />

  <meta name="citation_publisher" content="Public Library of Science"/>
  <meta name="citation_doi" content="10.1371/journal.pone.0000552"/>
  <meta name="dc.identifier" content="10.1371/journal.pone.0000552" />

    <meta name="citation_title" content="Patient and Regimen Characteristics Associated with Self-Reported Nonadherence to Antiretroviral Therapy"/>
    <meta itemprop="name" content="Patient and Regimen Characteristics Associated with Self-Reported Nonadherence to Antiretroviral Therapy"/>

      <meta name="citation_author" content="Patrick S. Sullivan"/>
            <meta name="citation_author_institution" content="Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America"/>
      <meta name="citation_author" content="Michael L. Campsmith"/>
            <meta name="citation_author_institution" content="Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America"/>
      <meta name="citation_author" content="Glenn V. Nakamura"/>
            <meta name="citation_author_institution" content="Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America"/>
      <meta name="citation_author" content="Elin B. Begley"/>
            <meta name="citation_author_institution" content="Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America"/>
      <meta name="citation_author" content="Jeffrey Schulden"/>
            <meta name="citation_author_institution" content="Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America"/>
      <meta name="citation_author" content="Allyn K. Nakashima"/>
            <meta name="citation_author_institution" content="Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America"/>

    <meta name="citation_date" content="2007/6/20"/>

  <meta name="citation_pdf_url" content="http://dx.plos.org/10.1371/journal.pone.0000552.pdf" />

      <meta name="citation_journal_title" content="PLOS ONE" />
    <meta name="citation_firstpage" content="e552"/>
    <meta name="citation_issue" content="6"/>
    <meta name="citation_volume" content="2"/>
    <meta name="citation_issn" content="1932-6203"/>

    <meta name="citation_journal_abbrev" content="PLoS ONE" />

      <meta name="citation_reference" content="citation_title=Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel.; citation_author=CC Carpenter; citation_author=MA Fischl; citation_author=SM Hammer; citation_author=MS Hirsch; citation_author=DM Jacobsen; citation_journal_title=JAMA; citation_volume=280; citation_number=1; citation_pages=78-86; citation_date=1998; " />
      <meta name="citation_reference" content="citation_title=Adherence to protease inhibitor therapy and outcomes in patients with HIV infection.; citation_author=DL Paterson; citation_author=S Swindells; citation_author=J Mohr; citation_author=M Brester; citation_author=EN Vergis; citation_journal_title=Ann Intern Med; citation_volume=133; citation_number=2; citation_pages=21-30; citation_date=2000; " />
      <meta name="citation_reference" content="citation_title=Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society–USA Panel.; citation_author=MS Hirsch; citation_author=B Conway; citation_author=RT D'Aquila; citation_author=VA Johnson; citation_author=F Brun-Vezinet; citation_journal_title=JAMA; citation_volume=279; citation_number=3; citation_pages=1984-1991; citation_date=1998; " />
      <meta name="citation_reference" content="citation_title=The impact of adherence on CD4 cell count responses among HIV-infected patients.; citation_author=E Wood; citation_author=RS Hogg; citation_author=B Yip; citation_author=PR Harrigan; citation_author=MV O'Shaughnessy; citation_journal_title=J Acquir Immune Defic Syndr; citation_volume=35; citation_number=4; citation_pages=261-268; citation_date=2004; " />
      <meta name="citation_reference" content="citation_author=M Cohen; citation_number=5; " />
      <meta name="citation_reference" content="citation_title=Quantitation of human immunodeficiency virus type 1 during pregnancy: relationship of viral titer to mother-to-child transmission and stability of viral load.; citation_author=B Weiser; citation_author=S Nachman; citation_author=P Tropper; citation_author=KH Viscosi; citation_author=R Grimson; citation_journal_title=Proc Natl Acad Sci USA; citation_volume=91; citation_number=6; citation_pages=8037-8041; citation_date=1994; " />
      <meta name="citation_reference" content="citation_title=Sexual and drug risk-related behaviours after initiating highly active antiretroviral therapy among injection drug users.; citation_author=D Vlahov; citation_author=M Safaien; citation_author=S Lai; citation_author=SA Strathdee; citation_author=L Johnson; citation_journal_title=AIDS; citation_volume=15; citation_number=7; citation_pages=2311-2316; citation_date=2001; " />
      <meta name="citation_reference" content="citation_title=The HIV behavioral surveillance program in the US: a conceptual framework.; citation_author=A Lansky; citation_author=PS Sullivan; citation_author=K Gallagher; citation_author=PL Fleming; citation_journal_title=Public Health Reports; citation_volume=122; citation_number=8; citation_pages=16-23; citation_date=2007; " />
      <meta name="citation_reference" content="citation_title=Adherence to antiretroviral therapies: state of the science.; citation_author=NR Reynolds; citation_journal_title=Curr HIV Res; citation_volume=2; citation_number=9; citation_pages=207-214; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature.; citation_author=A Ammassari; citation_author=MP Trotta; citation_author=R Murri; citation_author=F Castelli; citation_author=P Narciso; citation_journal_title=J Acquir Immune Defic Syndr; citation_volume=31; citation_number=10; citation_pages=S123-S127; citation_date=2002; " />
      <meta name="citation_reference" content="citation_title=Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens.; citation_author=MP Trotta; citation_author=A Ammassari; citation_author=A Cozzi-Lepri; citation_author=M Zaccarelli; citation_author=F Castelli; citation_journal_title=AIDS; citation_volume=17; citation_number=11; citation_pages=1099-1102; citation_date=2003; " />
      <meta name="citation_reference" content="citation_title=The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials.; citation_author=S Mannheimer; citation_author=G Friedland; citation_author=J Matts; citation_author=C Child; citation_author=M Chesney; citation_journal_title=Clin Infect Dis; citation_volume=34; citation_number=12; citation_pages=1115-1121; citation_date=2002; " />
      <meta name="citation_reference" content="citation_title=Higher rates of viral suppression with nonnucleoside reverse transcriptase inhibitors compared to single protease inhibitors are not explained by better adherence.; citation_author=SD Weiser; citation_author=D Guzman; citation_author=ED Riley; citation_author=R Clark; citation_author=DR Bangsberg; citation_journal_title=HIV Clin Trials; citation_volume=5; citation_number=13; citation_pages=278-287; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors.; citation_author=F Maggiolo; citation_author=L Ravasio; citation_author=D Ripamonti; citation_author=G Gregis; citation_author=G Quinzan; citation_journal_title=Clin Infect Dis; citation_volume=40; citation_number=14; citation_pages=158-163; citation_date=2005; " />
      <meta name="citation_reference" content="citation_title=Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study.; citation_author=TR Glass; citation_author=GS De; citation_author=R Weber; citation_author=PL Vernazza; citation_author=M Rickenbach; citation_journal_title=J Acquir Immune Defic Syndr; citation_volume=41; citation_number=15; citation_pages=385-392; citation_date=2006; " />
      <meta name="citation_reference" content="citation_title=Factors associated with nonadherence to highly active antiretroviral therapy: a 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase.; citation_author=MP Carrieri; citation_author=C Leport; citation_author=C Protopopescu; citation_author=JP Cassuto; citation_author=E Bouvet; citation_journal_title=J Acquir Immune Defic Syndr; citation_volume=41; citation_number=16; citation_pages=477-485; citation_date=2006; " />
      <meta name="citation_reference" content="citation_title=Addressing the challenges of adherence.; citation_author=JA Bartlett; citation_journal_title=J Acquir Immune Defic Syndr; citation_volume=29; citation_number=17; citation_pages=S2-10; citation_date=2002; " />
      <meta name="citation_reference" content="citation_title=Patient-reported and physician-estimated adherence to HAART: social and clinic center-related factors are associated with discordance.; citation_author=R Murri; citation_author=A Ammassari; citation_author=MP Trotta; citation_author=LA De; citation_author=S Melzi; citation_journal_title=J Gen Intern Med; citation_volume=19; citation_number=18; citation_pages=1104-1110; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=Long-term utility of measuring adherence by self-report compared with pharmacy record in a routine clinic setting.; citation_author=CK Fairley; citation_author=A Permana; citation_author=TR Read; citation_journal_title=HIV Med; citation_volume=6; citation_number=19; citation_pages=366-369; citation_date=2005; " />
      <meta name="citation_reference" content="citation_title=Adherence in clinical trials and in clinical practice.; citation_author=JC Walsh; citation_journal_title=Antivir Ther; citation_volume=4; citation_number=20; citation_pages=49-54; citation_date=1999; " />
      <meta name="citation_reference" content="citation_title=Measuring adherence to highly active antiretroviral therapy: implications for research and practice.; citation_author=T Kerr; citation_author=J Walsh; citation_author=E Lloyd-Smith; citation_author=E Wood; citation_journal_title=Curr HIV/AIDS Rep; citation_volume=2; citation_number=21; citation_pages=200-205; citation_date=2005; " />
      <meta name="citation_reference" content="citation_title=Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG).; citation_author=MA Chesney; citation_author=JR Ickovics; citation_author=DB Chambers; citation_author=AL Gifford; citation_author=J Neidig; citation_journal_title=AIDS Care; citation_volume=12; citation_number=22; citation_pages=255-266; citation_date=2000; " />
      <meta name="citation_reference" content="citation_title=Four measures of antiretroviral medication adherence and virologic response in AIDS Clinical Trials Group Study 359.; citation_author=CV Fletcher; citation_author=MA Testa; citation_author=RC Brundage; citation_author=MA Chesney; citation_author=R Haubrich; citation_journal_title=J Acquir Immune Defic Syndr; citation_volume=40; citation_number=23; citation_pages=301-306; citation_date=2005; " />
      <meta name="citation_reference" content="citation_title=Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART.; citation_author=A Antinori; citation_author=A Cozzi-Lepri; citation_author=A Ammassari; citation_author=MP Trotta; citation_author=D Nauwelaers; citation_journal_title=Antivir Ther; citation_volume=9; citation_number=24; citation_pages=291-296; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome.; citation_author=JC Walsh; citation_author=S Mandalia; citation_author=BG Gazzard; citation_journal_title=AIDS; citation_volume=16; citation_number=25; citation_pages=269-277; citation_date=2002; " />
      <meta name="citation_reference" content="citation_title=Self-reported measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management.; citation_author=JM Simoni; citation_author=A Hurth; citation_author=C Pearson; citation_author=D Panatalone; citation_author=J Merril; citation_journal_title=AIDS Behav; citation_volume=10; citation_number=26; citation_pages=199-212; citation_date=2006; " />
      <meta name="citation_reference" content="citation_title=Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: a meta-analysis.; citation_author=PT Nieuwkerk; citation_author=FJ Oort; citation_journal_title=J Acquir Immune Defic Syndr; citation_volume=38; citation_number=27; citation_pages=445-448; citation_date=2005; " />
      <meta name="citation_reference" content="citation_title=The supplement to HIV-AIDS Surveillance project: an approach for monitoring HIV risk behaviors.; citation_author=JW Buehler; citation_author=T Diaz; citation_author=BS Hersh; citation_author=SY Chu; citation_journal_title=Public Health Rep; citation_volume=111; citation_number=28; citation_pages=133-7; citation_date=1996; " />
      <meta name="citation_reference" content="citation_title=Alcohol use disorders: screening and diagnosis.; citation_author=SA Maisto; citation_author=R Saitz; citation_journal_title=Am J Addict; citation_volume=12; citation_number=29; citation_pages=S12-S25; citation_date=2003; " />
      <meta name="citation_reference" content="citation_title=Spectrum of disease in persons with human immunodeficiency virus infection in the United States.; citation_author=KM Farizo; citation_author=JW Buehler; citation_author=ME Chamberland; citation_author=BM Whyte; citation_author=ES Froelicher; citation_journal_title=JAMA; citation_volume=267; citation_number=30; citation_pages=1798-1805; citation_date=1992; " />
      <meta name="citation_reference" content="citation_title=Modelling the association between adherence and viral load in HIV-infected patients.; citation_author=B Vrijens; citation_author=E Goetghebeur; citation_author=E de Klerk; citation_author=R Rode; citation_author=S Mayer; citation_journal_title=Stat Med; citation_volume=24; citation_number=31; citation_pages=2719-2731; citation_date=2005; " />
      <meta name="citation_reference" content="citation_title=Older age and the response to and tolerability of antiretroviral therapy.; citation_author=MJ Silverberg; citation_author=W Leyden; citation_author=MA Horberg; citation_author=GN DeLorenze; citation_author=D Klein; citation_journal_title=Arch Intern Med; citation_volume=167; citation_number=32; citation_pages=684-691; citation_date=2007; " />
      <meta name="citation_reference" content="citation_title=Factors affecting adherence and convenience in antiretroviral therapy.; citation_author=A Lafeuillade; citation_journal_title=Int J STD AIDS; citation_volume=12; citation_number=33; citation_pages=18-24; citation_date=2001; " />
      <meta name="citation_reference" content="citation_title=Gender differences in factors associated with adherence to antiretroviral therapy.; citation_author=KM Berg; citation_author=PA Demas; citation_author=AA Howard; citation_author=EE Schoenbaum; citation_author=MN Gourevitch; citation_journal_title=J Gen Intern Med; citation_volume=19; citation_number=34; citation_pages=1111-1117; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=Adherence to highly active antiretroviral therapy in the homeless population in San Francisco: a prospective study.; citation_author=AR Moss; citation_author=JA Hahn; citation_author=S Perry; citation_author=ED Charlebois; citation_author=D Guzman; citation_journal_title=Clin Infect Dis; citation_volume=39; citation_number=35; citation_pages=1190-1198; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women.; citation_author=AA Howard; citation_author=JH Arnsten; citation_author=Y Lo; citation_author=D Vlahov; citation_author=JD Rich; citation_journal_title=AIDS; citation_volume=16; citation_number=36; citation_pages=2175-2182; citation_date=2002; " />
      <meta name="citation_reference" content="citation_title=Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users.; citation_author=JH Arnsten; citation_author=PA Demas; citation_author=RW Grant; citation_author=MN Gourevitch; citation_author=H Farzadegan; citation_journal_title=J Gen Intern Med; citation_volume=17; citation_number=37; citation_pages=377-381; citation_date=2002; " />
      <meta name="citation_reference" content="citation_title=Illicit drug use: can it predict adherence to antiretroviral therapy?; citation_author=M Martini; citation_author=E Recchia; citation_author=P Nasta; citation_author=D Castanotto; citation_author=F Chiaffarino; citation_journal_title=Eur J Epidemiol; citation_volume=19; citation_number=38; citation_pages=585-587; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=Sociodemographic and psychological variables influencing adherence to antiretroviral therapy.; citation_author=V Gordillo; citation_author=J del Amo; citation_author=V Soriano; citation_author=J Gonzalez-Lahoz; citation_journal_title=AIDS; citation_volume=13; citation_number=39; citation_pages=1763-1769; citation_date=1999; " />
      <meta name="citation_reference" content="citation_title=Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons.; citation_author=A Ammassari; citation_author=A Antinori; citation_author=MS Aloisi; citation_author=MP Trotta; citation_author=R Murri; citation_journal_title=Psychosomatics; citation_volume=45; citation_number=40; citation_pages=394-402; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy.; citation_author=F Starace; citation_author=A Ammassari; citation_author=MP Trotta; citation_author=R Murri; citation_author=LP De; citation_journal_title=J Acquir Immune Defic Syndr; citation_volume=31; citation_number=41; citation_pages=S136-S139; citation_date=2002; " />
      <meta name="citation_reference" content="citation_title=Incidence and impact of posttraumatic stress disorder and comorbid depression on adherence to HAART and CD4+ counts in people living with HIV.; citation_author=EM Sledjeski; citation_author=DL Delahanty; citation_author=LM Bogart; citation_journal_title=AIDS Patient Care STDS; citation_volume=19; citation_number=42; citation_pages=728-736; citation_date=2005; " />
      <meta name="citation_reference" content="citation_title=Substance abuse and psychiatric disorders in HIV-positive patients : epidemiology and impact on antiretroviral therapy.; citation_author=G Chander; citation_author=S Himelhoch; citation_author=RD Moore; citation_journal_title=Drugs; citation_volume=66; citation_number=43; citation_pages=769-789; citation_date=2006; " />
      <meta name="citation_reference" content="citation_title=Simplified regimens for treating HIV infection and AIDS.; citation_author=PJ Piliero; citation_author=JP Colagreco; citation_journal_title=J Am Acad Nurse Pract; citation_volume=15; citation_number=44; citation_pages=305-312; citation_date=2003; " />
      <meta name="citation_reference" content="citation_title=Self-perception of body changes in persons living with HIV/AIDS: prevalence and associated factors.; citation_author=CP Santos; citation_author=YX Felipe; citation_author=PE Braga; citation_author=D Ramos; citation_author=RO Lima; citation_journal_title=AIDS; citation_volume=19; citation_number=45; citation_pages=S14-S21; citation_date=2005; " />
      <meta name="citation_reference" content="citation_title=Redefining lipodystrophy syndrome: risks and impact on clinical decision making.; citation_author=KA Lichtenstein; citation_journal_title=J Acquir Immune Defic Syndr; citation_volume=39; citation_number=46; citation_pages=395-400; citation_date=2005; " />
      <meta name="citation_reference" content="citation_title=Boosted PIs are more forgiving of suboptimal adherence than non-boosted PIs or NNRTIs.; citation_author=R Gross; citation_author=B Yip; citation_author=E Wood; citation_author=D Bangsberg; citation_author=A Justice; citation_author=J Montaner; citation_number=47; " />
      <meta name="citation_reference" content="citation_title=Adherence to antiretroviral HIV drugs: how many doses can you miss before resistance emerges?; citation_author=RJ Smith; citation_journal_title=Proc Biol Sci; citation_volume=273; citation_number=48; citation_pages=617-624; citation_date=2006; " />
      <meta name="citation_reference" content="citation_title=Nonadherence to highly active antiretroviral therapy: clinically relevant patient categorization based on electronic event monitoring.; citation_author=E Van Wijngaerden; citation_author=V De Saar; citation_author=V DeGraeve; citation_author=AM Vandamme; citation_author=K Van Vaerenbergh; citation_journal_title=AIDS Res Hum Retroviruses; citation_volume=18; citation_number=49; citation_pages=327-330; citation_date=2002; " />
      <meta name="citation_reference" content="citation_title=Bias in analytic research.; citation_author=DL Sackett; citation_journal_title=J Chronic Dis; citation_volume=32; citation_number=50; citation_pages=51-63; citation_date=1979; " />
      <meta name="citation_reference" content="citation_title=Is the influence of social desirability on patients' self-reported adherence overrated?; citation_author=G Wagner; citation_author=LG Miller; citation_journal_title=J Acquir Immune Defic Syndr; citation_volume=35; citation_number=51; citation_pages=203-204; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=Trust and the acceptance of and adherence to antiretroviral therapy.; citation_author=FL Altice; citation_author=F Mostashari; citation_author=GH Friedland; citation_journal_title=J Acquir Immune Defic Syndr; citation_volume=28; citation_number=52; citation_pages=47-58; citation_date=2001; " />
      <meta name="citation_reference" content="citation_title=HIV-seropositive individuals' optimistic beliefs about prognosis and relation to medication and safe sex adherence.; citation_author=WC Holmes; citation_author=JL Pace; citation_journal_title=J Gen Intern Med; citation_volume=17; citation_number=53; citation_pages=677-683; citation_date=2002; " />
      <meta name="citation_reference" content="citation_title=Baseline predictors of three types of antiretroviral therapy (ART) adherence: a 2-year follow-up.; citation_author=SL Nilsson; citation_author=PM Diamond; citation_author=MW Ross; citation_author=M Williams; citation_author=G Bratt; citation_journal_title=AIDS Care; citation_volume=18; citation_number=54; citation_pages=246-253; citation_date=2006; " />
      <meta name="citation_reference" content="citation_title=Predictors of antiretroviral adherence as measured by self-report, electronic monitoring, and medication diaries.; citation_author=GJ Wagner; citation_journal_title=AIDS Patient Care STDS; citation_volume=16; citation_number=55; citation_pages=599-608; citation_date=2002; " />
      <meta name="citation_reference" content="citation_title=Neurocognitive aspects of medication adherence in HIV infection.; citation_author=OA Selnes; citation_journal_title=J Acquir Immune Defic Syndr; citation_volume=31; citation_number=56; citation_pages=S132-S135; citation_date=2002; " />
      <meta name="citation_reference" content="citation_title=The role of HIV serostatus disclosure in antiretroviral medication adherence.; citation_author=MJ Stirratt; citation_author=RH Remien; citation_author=A Smith; citation_author=OQ Copeland; citation_author=C Dolezal; citation_journal_title=AIDS Behav; citation_volume=10; citation_number=57; citation_pages=483-493; citation_date=2006; " />
      <meta name="citation_reference" content="citation_title=Life stress and adherence to antiretroviral therapy among HIV-positive individuals: a preliminary investigation.; citation_author=KA Bottonari; citation_author=JE Roberts; citation_author=JA Ciesla; citation_author=RG Hewitt; citation_journal_title=AIDS Patient Care STDS; citation_volume=19; citation_number=58; citation_pages=719-727; citation_date=2005; " />
      <meta name="citation_reference" content="citation_title=Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents: adherence to potent antiretroviral therapy.; citation_number=59; citation_date=2006; " />
      <meta name="citation_reference" content="citation_title=Behavioral surveillance among persons risk for HIV infection in the United States: The National HIV Behavioral Surveillance System.; citation_author=KM Gallagher; citation_author=PS Sullivan; citation_author=A Lansky; citation_author=IM Onorato; citation_journal_title=Public Health Reports; citation_volume=122; citation_number=60; citation_pages=32-38; citation_date=2007; " />

  <link rel="canonical" href="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0000552" />

    <meta name="twitter:card" content="summary"/>
    <meta name="twitter:site" content="@plosone"/>
    <meta name="twitter:title" content="Patient and Regimen Characteristics Associated with Self-Reported Nonadherence to Antiretroviral Therapy"/>
    <meta name="twitter:description" content="BackgroundNonadherence to antiretroviral therapy (ARVT) is an important behavioral determinant of the success of ARVT. Nonadherence may lead to virological failure, and increases the risk of development of drug resistance. Understanding the prevalence of nonadherence and associated factors is important to inform secondary HIV prevention efforts.Methodology/Principal FindingsWe used data from a cross-sectional interview study of persons with HIV conducted in 18 U.S. states from 2000&ndash;2004. We calculated the proportion of nonadherent respondents (took &lt;95% of prescribed doses in the past 48 hours), and the proportion of doses missed. We used multivariate logistic regression to describe factors associated with nonadherence. Nine hundred and fifty-eight (16%) of 5,887 respondents reported nonadherence. Nonadherence was significantly (p&lt;0.05) associated with black race and Hispanic ethnicity; age &lt;40 years; alcohol or crack use in the prior 12 months; being prescribed &ge;4 medications; living in a shelter or on the street; and feeling &ldquo;blue&rdquo; &ge;14 of the past 30 days. We found weaker associations with having both male-male sex and injection drug use risks for HIV acquisition; being prescribed ARVT for &ge;21 months; and being prescribed a protease inhibitor (PI)-based regimen not boosted with ritonavir. The median proportion of doses missed was 50%. The most common reasons for missing doses were forgetting and side effects.Conclusions/SignificanceSelf-reported recent nonadherence was high in our study. Our data support increased emphasis on adherence in clinical settings, and additional research on how providers and patients can overcome barriers to adherence."/>
      <meta name="twitter:image" content="http://dx.plos.org/10.1371/journal.pone.0000552.t002"/>

  <meta property="og:title" content="Patient and Regimen Characteristics Associated with Self-Reported Nonadherence to Antiretroviral Therapy" />
  <meta property="og:type" content="article" />
  <meta property="og:url" content="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0000552" />

 <!--end articleInfoX-->

  <link rel="pingback" href="http://www.plosone.org/pingback" />


  <link rel="shortcut icon" href="/images/favicon.ico" type="image/x-icon"/>
  <link rel="home" title="home" href="/"/>
  <link rel="alternate" type="application/rss+xml"
        title="PLOS ONE: New Articles"
        href="http://www.plosone.org/article/feed"/>
</head>
<body>

  <div id="page-wrap">
    <div id="topbanner" class="cf">

<!-- Div for the ad at the top of journal home page-->
<div class="center">
  <div class="title">Advertisement</div>
  <iframe id='a3ac9da4' name='a3ac9da4'
    src='http://ads.plos.org/www/delivery/afr.php?zoneid=345&amp;cb=2935'
    frameborder='0' scrolling='no' width='730' height='90'>
    <a href='http://ads.plos.org/www/delivery/ck.php?n=a3ac9da4&amp;cb=2743'
      target='_top'><img src='http://ads.plos.org/www/delivery/avw.php?zoneid=345&amp;cb=8122&amp;n=a3ac9da4'
      border='0' alt=''/>
    </a>
  </iframe>
</div>    </div>

    <div id="pagehdr-wrap">
      <div id="pagehdr">
        <div id="user" class="nav">
          <ul>
            <li><a href="http://www.plos.org">plos.org</a></li>
            <li><a href="https://register.plos.org/ambra-registration/register.action">create account</a></li>
            <li class="btn-style"><a
              href="/user/secure/secureRedirect.action?goTo=%2Farticle%2FfetchArticle.action%3FarticleURI%3Dinfo%253Adoi%252F10.1371%252Fjournal.pone.0000552">sign in</a>
            </li>
          </ul>
        </div>
        <div class="logo">
          <a href="/"><img src="/images/logo.png" alt="PLOS ONE"></a>
        </div>

<div id="nav-main" class="nav">
  <ul>
        <li id="mn-01"><a href="/taxonomy" class="areas-link">Subject Areas</a></li>
    <li id="mn-02"><a href="javascript:void(0);">For Authors</a>
      <div class="submenu" style="width: 540px; margin-left: -300px;">
        <div class="block">
          <div class="submit-script">
            <h3>Submit your Manuscript</h3>
            <ul>
              <li>Fair, rigorous peer review</li>
              <li>Broad scope and wide reach</li>
            </ul>
            <a href="/static/submissionInstructions" class="btn">get started</a>
          </div>
        </div>
        <div class="menu">
          <ul>
            <li><a href="/static/publish">Why Publish with PLOS ONE</a></li>
            <li><a href="/static/publication">Publication Criteria</a></li>
            <li><a href="/static/editorial">Editorial Policies</a></li>
            <li><a href="/static/guidelines">Preparing A Manuscript</a></li>
            <li><a href="/static/figureGuidelines">Figure and Table Guidelines</a></li>
          <li><a href="/static/supportingInformation">Supporting Information Guidelines</a></li>
            <li><a href="/static/submissionInstructions">Submitting a Manuscript</a></li>
          </ul>
        </div>
      </div>
    </li>

    <li id="mn-03"><a href="javascript:void(0);">About Us</a>
      <div class="submenu" style="width:248px; margin-left:-30px;">
        <div class="menu">
          <ul>
            <li><a href="/static/information">Journal Information</a></li>
            <li><a href="/static/edboard">Editorial Board</a></li>
            <li><a href="/static/reviewerGuidelines">Reviewer Guidelines</a></li>
            <li><a href="/static/almInfo">Article-Level Metrics</a></li>
            <li><a href="/static/license">Open-Access License</a></li>
            <li><a href="/static/downloads">Media Downloads</a></li>
            <li><a href="/static/commentGuidelines">Guidelines for Comments</a></li>
            <li><a href="/static/corrections">Corrections</a></li>
            <li><a href="/static/help">Help Using this Site</a></li>
            <li><a href="/static/contact">Contact Us</a></li>
          </ul>
        </div>
      </div>
    </li>
  </ul>
<div id="db">
  <form name="searchForm" action="/search/simple?noSearchFlag=true&amp;query=&amp;articleURI=info%3Adoi%2F10.1371%2Fjournal.pone.0000552" method="get" >
<input type="hidden" name="from" value="globalSimpleSearch" id="from"/><input type="hidden" name="filterJournals" value="PLoSONE" id="filterJournals"/>    <fieldset>
      <legend>Search</legend>
      <label for="search">Search</label>
      <div class="wrap">
        <input id="search" type="text" name="query" placeholder="Search">
        <input type="image" alt="SEARCH" src="/images/icon.search.gif">
      </div>
    </fieldset>
  </form>
    <a id="advSearch" href="/search/advanced?noSearchFlag=true&amp;query=&amp;articleURI=info%3Adoi%2F10.1371%2Fjournal.pone.0000552&filterJournals=PLoSONE">advanced search</a>
</div></div>

      </div>
      <!-- pagehdr-->
    </div>
    <!-- pagehdr-wrap -->

  <!--body and html tags gets closed in global_footer.ftl-->
<script type="text/javascript" src="/javascript/mathjax/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>

<div id="pagebdy-wrap">
  <div id="pagebdy">

    <div id="article-block" class="cf">

<div class="article-meta cf">
  <ul id="almSignPost" style="display: none;"></ul>
  <div class="article-type">
    <span class="type oa">Open Access</span>
      <span class="type pr">Peer-Reviewed</span>
  </div>
</div>

<div class="header" id="hdr-article">

<div class="article-kicker">
      <span id="article-type-heading">
        Research Article
      </span>
</div>  <h1 property="dc:title" datatype="" rel="dc:type" href="http://purl.org/dc/dcmitype/Text">
    Patient and Regimen Characteristics Associated with Self-Reported Nonadherence to Antiretroviral Therapy
  </h1>

  <ul class="authors">
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Patrick S. Sullivan
              <span class="corresponding">mail</span>, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              <p><span class="email">*</span>To whom correspondence should be addressed. E-mail: <a href="mailto:pss0@cdc.gov">pss0@cdc.gov</a></p>

                <p>Affiliation:
                  Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Michael L. Campsmith, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Glenn V. Nakamura, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Elin B. Begley, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Jeffrey Schulden, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Allyn K. Nakashima
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
  </ul>
  <ul class="date-doi-line">
    <li>Published: June 20, 2007</li>
    <li>DOI: 10.1371/journal.pone.0000552</li>
  </ul>


</div><!--end header-->
<div class="main cf" id="pjax-container">
  

<div class="nav items-5" id="nav-article">
  <ul>
  <li>
        <span class="active" name="article">Article</span>
  </li>
  <li>
      <a href="/article/authors/info%3Adoi%2F10.1371%2Fjournal.pone.0000552" name="authors">About the Authors</a>
  </li>
  <li>
      <a href="/article/metrics/info%3Adoi%2F10.1371%2Fjournal.pone.0000552" name="metrics">Metrics</a>
  </li>
  <li>
      <a href="/article/comments/info%3Adoi%2F10.1371%2Fjournal.pone.0000552" name="comments">Comments</a>
  </li>
  <li>
      <a href="/article/related/info%3Adoi%2F10.1371%2Fjournal.pone.0000552" name="related">Related Content</a>
  </li>
  </ul>
</div>

<script type="text/javascript">
  var selected_tab = "article";
</script>
  <div id="figure-thmbs" class="carousel cf">
    <div class="wrapper">
      <div class="slider">
              <div class="item">
                <a href="#pone-0000552-t001" data-doi="info:doi/10.1371/journal.pone.0000552" data-uri="info:doi/10.1371/journal.pone.0000552.t001" title="Table 1">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000552.t001&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
              <div class="item">
                <a href="#pone-0000552-t002" data-doi="info:doi/10.1371/journal.pone.0000552" data-uri="info:doi/10.1371/journal.pone.0000552.t002" title="Table 2">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000552.t002&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
      </div>
    </div>
  </div>

  <div class="nav-col">
    <div class="nav" id="nav-article-page">
      <ul>
        <li class="nav-col-comments"><a href="/article/comments/info%3Adoi%2F10.1371%2Fjournal.pone.0000552">Reader Comments (0)</a></li>
          <li id="nav-figures"><a data-doi="info:doi/10.1371/journal.pone.0000552" >Figures</a></li>
      </ul>
    </div>
  </div>

  <div class="article">







<div class="abstract"><a id="abstract0" name="abstract0" toc="abstract0" title="Abstract"></a><h2>Abstract</h2>
<h3>Background</h3>
<a id="article1.front1.article-meta1.abstract1.sec1.p1" name="article1.front1.article-meta1.abstract1.sec1.p1"></a><p>Nonadherence to antiretroviral therapy (ARVT) is an important behavioral determinant of the success of ARVT. Nonadherence may lead to virological failure, and increases the risk of development of drug resistance. Understanding the prevalence of nonadherence and associated factors is important to inform secondary HIV prevention efforts.</p>


<h3>Methodology/Principal Findings</h3>
<a id="article1.front1.article-meta1.abstract1.sec2.p1" name="article1.front1.article-meta1.abstract1.sec2.p1"></a><p>We used data from a cross-sectional interview study of persons with HIV conducted in 18 U.S. states from 2000–2004. We calculated the proportion of nonadherent respondents (took &lt;95% of prescribed doses in the past 48 hours), and the proportion of doses missed. We used multivariate logistic regression to describe factors associated with nonadherence. Nine hundred and fifty-eight (16%) of 5,887 respondents reported nonadherence. Nonadherence was significantly (p&lt;0.05) associated with black race and Hispanic ethnicity; age &lt;40 years; alcohol or crack use in the prior 12 months; being prescribed ≥4 medications; living in a shelter or on the street; and feeling “blue” ≥14 of the past 30 days. We found weaker associations with having both male-male sex and injection drug use risks for HIV acquisition; being prescribed ARVT for ≥21 months; and being prescribed a protease inhibitor (PI)-based regimen not boosted with ritonavir. The median proportion of doses missed was 50%. The most common reasons for missing doses were forgetting and side effects.</p>


<h3>Conclusions/Significance</h3>
<a id="article1.front1.article-meta1.abstract1.sec3.p1" name="article1.front1.article-meta1.abstract1.sec3.p1"></a><p>Self-reported recent nonadherence was high in our study. Our data support increased emphasis on adherence in clinical settings, and additional research on how providers and patients can overcome barriers to adherence.</p>

</div>


<div class="articleinfo"><p><strong>Citation: </strong>Sullivan PS, Campsmith ML, Nakamura GV, Begley EB, Schulden J, et al.  (2007) Patient and Regimen Characteristics Associated with Self-Reported Nonadherence to Antiretroviral Therapy. PLoS ONE 2(6):
          e552.
            doi:10.1371/journal.pone.0000552</p><p><strong>Academic Editor: </strong>Linqi Zhang, AIDS Research Center, Chinese Academy of Medical Sciences and Peking Union Medical College, China</p><p><strong>Received:</strong> November 3, 2006; <strong>Accepted:</strong> May 30, 2007; <strong>Published:</strong> June 20, 2007</p><p>This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.</p><p><strong>Funding: </strong>Funding support for data collection was provided to the project sites by the Centers for Disease Control and Prevention. No external funding was used to support the analysis of these data.</p><p><strong>Competing interests:</strong> The authors have declared that no competing interests exist.</p></div>





<div id="section1" class="section"><a id="s1" name="s1" toc="s1" title="Introduction"></a><h3>Introduction</h3><a id="article1.body1.sec1.p1" name="article1.body1.sec1.p1"></a><p>The full benefit of antiretroviral therapy (ARVT) in HIV-infected patients requires patients to be prescribed appropriate therapy, the virus to be sensitive to the prescribed therapy, and patients to adhere to the prescribed regimen <a href="#pone.0000552-Carpenter1">[1]</a>. Evidence from clinical trials suggests that very high levels of adherence (&gt;95%) are required for optimally suppressing viral load and preventing the emergence of resistant virus <a href="#pone.0000552-Paterson1">[2]</a>, <a href="#pone.0000552-Hirsch1">[3]</a>. Even among those with low CD4 counts at the initiation of ARVT, adherence is a strong predictor of increase in CD4 count after initiation of combination ARVT <a href="#pone.0000552-Wood1">[4]</a>. There may also be significant public health benefits associated with prescription of antiretroviral therapy and good adherence: on a population basis, lower viral loads are predicted to be associated with decreased sexual <a href="#pone.0000552-Cohen1">[5]</a>, perinatal <a href="#pone.0000552-Weiser1">[6]</a>, and injection-related <a href="#pone.0000552-Vlahov1">[7]</a> transmission of HIV.</p>
<a id="article1.body1.sec1.p2" name="article1.body1.sec1.p2"></a><p>Therefore, understanding the prevalence of nonadherence, its associated factors, and reasons for nonadherence is an important clinical and public health goal. Behaviors, such as adherence, that are related to HIV disease progression are measured as part of behavioral surveillance projects conducted in the United States <a href="#pone.0000552-Lansky1">[8]</a>. Generally, behavioral surveillance systems measure behaviors of interest in a large number of persons, but do not collect the same depth of information on specific topics that might be collected in smaller research studies.</p>
<a id="article1.body1.sec1.p3" name="article1.body1.sec1.p3"></a><p>Although many factors have been consistently reported to be associated with poor adherence (reviewed by Reynolds <a href="#pone.0000552-Reynolds1">[9]</a> and Ammasarri <a href="#pone.0000552-Ammassari1">[10]</a>), other associations are less clear. For many key demographic factors, as well as certain social and regimen-related factors, contradictory results appear in published literature <a href="#pone.0000552-Ammassari1">[10]</a>. Most recently, there have been contradictory reports as to whether some types of ARVT regimens (e.g., non-nucleoside reverse transcriptase inhibitor [NNRTI] -based regimens) may be associated with higher levels of adherence <a href="#pone.0000552-Trotta1">[11]</a>–<a href="#pone.0000552-Carrieri1">[16]</a>.</p>
<a id="article1.body1.sec1.p4" name="article1.body1.sec1.p4"></a><p>Methods for studying adherence are varied. They include electronic monitoring of access to medication bottles, examination of pharmacy records, physician estimation, and measurement of drug levels <a href="#pone.0000552-Bartlett1">[17]</a>–<a href="#pone.0000552-Kerr1">[21]</a>. These methods are costly, however, and may be difficult to implement in large behavioral surveillance projects. Although self-reported adherence is subject to limitations common to interview studies and likely overestimates adherence <a href="#pone.0000552-Murri1">[18]</a>, self-report provides a measure of adherence which generally correlates well with more objective methods <a href="#pone.0000552-Kerr1">[21]</a>–<a href="#pone.0000552-Simoni1">[26]</a> and with virologic treatment response <a href="#pone.0000552-Nieuwkerk1">[27]</a>. It is also practical for use in ongoing behavioral surveillance efforts. We report the results of an exploratory analysis of behavioral surveillance data on self-reported adherence from a multi-state supplemental surveillance study of persons with HIV infection.</p>
</div>

<div id="section2" class="section"><a id="s2" name="s2" toc="s2" title="Methods"></a><h3>Methods</h3>
<h4>Project</h4>
<a id="article1.body1.sec2.sec1.p1" name="article1.body1.sec2.sec1.p1"></a><p>The Supplement to HIV and AIDS Surveillance (SHAS) Project is a cross-sectional behavioral surveillance study of persons with HIV infection. The methods have been previously described <a href="#pone.0000552-Buehler1">[28]</a>. Briefly, adults, aged 18 years and older, reported with HIV or AIDS through routine case surveillance were eligible for participation. Participants were enrolled using one of two methods: 1) facility-based recruitment of all eligible persons seeking treatment at selected health care facilities in Denver, Colorado; Hartford and New Haven, Connecticut; Jacksonville, Miami, and Tampa, Florida; Atlanta, Georgia; Chicago, Illinois; Baltimore, Maryland; Detroit, Michigan; Jersey City and Paterson, New Jersey; and Philadelphia, Pennsylvania; or 2) population-based recruitment of all eligible persons in Phoenix and Tucson, Arizona; Delaware; Kansas; Los Angeles County, California; Minneapolis/St. Paul, Minnesota; New Mexico; South Carolina; Austin and Houston, Texas; and Washington. All sites interviewed persons reported with AIDS. Additionally, during the time period examined for this analysis, Arizona, Denver, Detroit, Florida, Kansas, Minnesota, New Jersey, New Mexico, South Carolina and Texas also interviewed persons with HIV infection which had not progressed to AIDS. Informed consent was obtained from all participants prior to the interview, and the study received institutional review board (IRB) approval at both the Centers for Disease Control and Prevention and local levels.</p>


<h4>Measures</h4>
<a id="article1.body1.sec2.sec2.p1" name="article1.body1.sec2.sec2.p1"></a><p>Beginning in May 2000, the SHAS Project added questions on medication history, adherence, and reasons for nonadherence. We utilized data from interviews conducted from May 2000 through June 2004 (when the project ended). Respondents who were prescribed antiretroviral therapy at the time of the interview were asked, “In the last 48 hours, have you missed or skipped any pills or spoonfuls of any of your antiretroviral medications?” We collected detailed information about the prescribed antiretroviral regimens at the time of the interview, including the number of daily doses prescribed for each medication. For respondents who reported missing one or more doses of medication in the 48 hours before interview, we asked about the number of doses missed, and calculated the total proportion of doses taken. We defined nonadherence as taking less than 95% of prescribed doses in the 48 hours before interview. We also asked the reasons why doses were missed and field coded the participants' responses using a list of possible reasons constructed by the investigators. Interviewers received training on administering the questionnaire, and used reference materials, including pictures of capsules of various medications, to help respondents identify their current prescriptions.</p>
<a id="article1.body1.sec2.sec2.p2" name="article1.body1.sec2.sec2.p2"></a><p>We defined protease inhibitor (PI)-based regimens as consisting of any 2 or more nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) plus any PI; boosted PI-based regimens as additionally including ritonavir; unboosted PI-based regimens as not including ritonavir; NNRTI-based regimens as consisting of any 2 or more NRTIs plus any NNRTI; triple NRTI therapy as consisting of any 3 or more NRTIs; and other ARVT as consisting of any one or more PI, NNRTI, NRTI, or pentafuside, but not meeting one of the previous definitions.</p>


<h4>Analyses of All SHAS Respondents</h4>
<a id="article1.body1.sec2.sec3.p1" name="article1.body1.sec2.sec3.p1"></a><p>We constructed a multivariate logistic regression model (PROC LOGISTIC, SAS Institute, Cary, NC) to calculate adjusted odd ratios and 95% confidence intervals for factors associated with nonadherence. We selected putative explanatory variables based on review of published biomedical literature. Our putative explanatory variables fell into several categories: demographic factors (age, race, sex, risk for acquiring HIV infection), socioeconomic status indicators (living situation, income, education, being on public assistance, and currently having health insurance) recent substance use behaviors (use of alcohol, crack, or injection drugs in the 12 months before the interview, and the CAGE questions <a href="#pone.0000552-Maisto1">[29]</a> for possible alcohol abuse), characteristics of the ARVT regimen (type of regimen, number of drugs in the regimen, and duration of ARVT treatment), aspects of HIV care (use of a reminder system for medications, and whether the healthcare provider had discussed antiretroviral resistance with the patient), and indicators of depression (“feeling blue” for ≥14 of the past 30 days, having limited activity for ≥14 of the past 30 days, reporting a current met or unmet need for mental health services, and history of incarceration).</p>
<a id="article1.body1.sec2.sec3.p2" name="article1.body1.sec2.sec3.p2"></a><p>To construct our model, we first examined correlation coefficients of all pairs of putative explanatory variables. Where significant correlations existed, we removed one of the two correlated variables from consideration. For example, being on public assistance was removed from consideration, but current income was retained for consideration. We conducted bivariate analyses for all remaining explanatory variables, and only those with a p value of &lt;0.25 from chi-square testing were considered in subsequent model building. Next we built a multivariate logistic regression model using manual forward selection. At each step, the remaining variable with the largest chi-square for its association with nonadherence was entered into the model, and inspected to determine if the associated p value in the model was &lt;0.05. Factors continued to be entered until the last factor entered had a p value of &gt;0.05. Once factors were entered into the model, they were not removed. The model was complete with respect to first order terms when no other variable could be entered and retained with a p value of &lt;0.05. After all first order terms were entered into the model, we checked all two-way interaction terms, using an experiment-wide alpha of 0.05 because of the large number of two-way terms tested. No significant two-way interaction term was identified.</p>
<a id="article1.body1.sec2.sec3.p3" name="article1.body1.sec2.sec3.p3"></a><p>We conducted a similar process of modeling, in which, for certain factors with multiple levels – race, age, risk for HIV acquisition, ARVT regimen type, regimen duration, and number of drugs in regimen – if any level of the factor was significant, all levels of the factor would be retained in the model, regardless of significance. The results of this model were essentially the same as the reduced model, so we chose to present the reduced model.</p>
<a id="article1.body1.sec2.sec3.p4" name="article1.body1.sec2.sec3.p4"></a><p>For those who reported nonadherence, we also calculated the proportion of doses missed in the 48 hours before the interview, and tabulated the main reasons reported for missing doses.</p>


<h4>Subgroup Analysis: Validation of Self-Reported Adherence Using Viral Load Measurements</h4>
<a id="article1.body1.sec2.sec4.p1" name="article1.body1.sec2.sec4.p1"></a><p>We validated our self-reported adherence outcome measure by using data from a subset of SHAS respondents prescribed ARVT at the time of interview who were also observed in the Adult and Adolescent Spectrum of HIV Disease (ASD) Project (a longitudinal medical records review project conducted in some of the same project areas as SHAS) <a href="#pone.0000552-Farizo1">[30]</a>. For those who were in both SHAS and ASD datasets, we determined the lowest HIV RNA concentration during the 6 month period including the SHAS interview date for each respondent. The distributions of HIV RNA concentration were not normal for either those who reported nonadherence or those who did not report nonadherence. Therefore, the median HIV RNA concentrations between the two groups were compared using the Wilcoxon Rank Sum test.</p>

</div>

<div id="section3" class="section"><a id="s3" name="s3" toc="s3" title="Results"></a><h3>Results</h3><a id="article1.body1.sec3.p1" name="article1.body1.sec3.p1"></a><p>From May 2000 through June 2004, 11,503 persons were offered enrollment in SHAS; 9,088 (79%) were interviewed, and 2,415 (21%) refused to participate. Thirty-nine of 5,926 respondents who were prescribed ARVT at the time of interview had insufficient information on daily doses prescribed or number of doses missed in the 48 hours before the interview, and were, therefore, excluded. Thus, for this analysis, we included 5,887 (65% of interviewed) respondents who had complete information on antiretroviral prescription and dosing and who reported being prescribed at least one antiretroviral medication at the time of interview. Out of 5,887 respondents, 520 had been interviewed in a state where ASD was also conducted, and had data from medical records abstractions that spanned the date of the SHAS interview. The 520 were included in the subgroup analyses for validation of self-reported adherence using viral loads. The characteristics of interviewed persons, persons who were prescribed ARVT at the time of interview and included in the analysis of nonadherence, and persons included in the subgroup viral load analysis, are reported in <a href="#pone-0000552-t001">Table 1</a>.</p>
<div class="figure" id="pone-0000552-t001"><div class="img"><a name="pone-0000552-t001" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000552.t001&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0000552" data-uri="info:doi/10.1371/journal.pone.0000552.t001"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000552.t001&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000552.t001/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000552.t001/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000552.t001/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000552.t001/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0000552.t001.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000552.t001/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000552.t001/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0000552.t001.TIF"></span>)
                </a></li></ul></div><p><strong>Table 1.  <span>Characteristics of persons with HIV infection interviewed in the Supplement to HIV and AIDS Surveillance Project, who were prescribed antiretroviral drugs at the time of interview, and who were included in subgroup analyses of viral load, 18 US states, 2000–2004</span></strong></p><span>doi:10.1371/journal.pone.0000552.t001</span></div>
<h4>Analyses of All SHAS Respondents</h4>
<a id="article1.body1.sec3.sec1.p1" name="article1.body1.sec3.sec1.p1"></a><p>Among all SHAS respondents prescribed at least one antiretroviral medication at the time of the interview, 958 (16%) reported nonadherence in the 48 hours before the interview. The results of multivariate logistic regression (<a href="#pone-0000552-t002">Table 2</a>) indicated that several groups were significantly (p&lt;0.05) more likely to report nonadherence: black non-Hispanic and Hispanic respondents (versus all other races); respondents aged 18–29 or 30–39 years (versus those aged ≥40 years); respondents who reported using alcohol or crack cocaine in the past 12 months; respondents prescribed ≥4 medications at the time of interview (versus 1–3 medications); respondents who had been blue for ≥14 of the past 30 days; and respondents currently living in a shelter or on the street (versus all other living situations). Respondents living in a medical facility were less likely to report nonadherence. Several additional factors were significantly associated with nonadherence, but had a weak or modest strength of association and lower bounds of the 95% CI close to 1.0. Such weak associations were observed for having both male-male sex and injecting drug use risks for HIV acquisition (versus all other acquisition modes); being prescribed an unboosted PI-based regimen (versus any other regimen); and being prescribed ARVT for ≥21 months (versus &lt;21 months).</p>
<div class="figure" id="pone-0000552-t002"><div class="img"><a name="pone-0000552-t002" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000552.t002&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0000552" data-uri="info:doi/10.1371/journal.pone.0000552.t002"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000552.t002&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000552.t002/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000552.t002/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000552.t002/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000552.t002/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0000552.t002.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000552.t002/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000552.t002/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0000552.t002.TIF"></span>)
                </a></li></ul></div><p><strong>Table 2.  <span>Characteristics of HIV infected persons interviewed about adherence to currently prescribed antiretroviral therapy, number and proportion of nonadherent respondents, and logistic regression model of factors associated with nonadherence among 5,887 respondents to the Supplement to HIV/AIDS Surveillance Project, 18 US States, 2000 to 2004</span></strong></p><span>doi:10.1371/journal.pone.0000552.t002</span></div><a id="article1.body1.sec3.sec1.p2" name="article1.body1.sec3.sec1.p2"></a><p>Among the 958 persons who were nonadherent, the median proportion of doses missed was 50% of doses. The mode of missed doses was 100%; 226 of 958 (24%) of nonadherent respondents reported taking no dose of medication during the previous 48 hours.</p>
<a id="article1.body1.sec3.sec1.p3" name="article1.body1.sec3.sec1.p3"></a><p>A total of 821 persons (86% of those who missed ≥5% of doses in the 48 hours before the interview) reported the most important reason that doses were missed. The most commonly reported reasons were forgetting to take the medicine (266 respondents, 32%); side effects from the medications (152 respondents, 16%); inability to get to the clinic or doctor for a prescription (106 respondents, 11%); and inability to fit medications into the respondent's schedule (84 respondents, 9%). Other reported main reasons included, getting depressed (28 respondents, 3%); not believing that the medications work (21 respondents, 2%); and being on the street, in jail, or in prison (7 respondents, 1%).</p>


<h4>Subgroup Analysis: Validation of Self-Reported Adherence Using Viral Load Measurements</h4>
<a id="article1.body1.sec3.sec2.p1" name="article1.body1.sec3.sec2.p1"></a><p>Results from the subgroup who had HIV RNA concentrations available for analysis indicated that the HIV RNA concentration was higher for the 64 persons who reported taking &lt;95% of prescribed doses in the 48 hours before the interview (median  =  400; range: undetectable – 425,000) than for the 397 persons who took ≥95% of prescribed doses (median  =  85; range: undetectable – 750,000; p  =  0.03 by 2-sided Wilcoxon Rank Sum Test). The HIV RNA measurements were taken a median of 36 days from the interview (interquartile range, 6–78 days).</p>

</div>

<div id="section4" class="section"><a id="s4" name="s4" toc="s4" title="Discussion"></a><h3>Discussion</h3><a id="article1.body1.sec4.p1" name="article1.body1.sec4.p1"></a><p>In a large, diverse group of persons living with HIV infection, we observed a magnitude of nonadherence that poses a considerable threat to the individual and public health benefits of ARVT. About 1 in 6 persons interviewed in our project had missed at least 5% of their prescribed ARVT doses in the 48 hours before the interview. Although we used a self-reported measure, the self-reported measure of adherence was related to virologic outcome among a subgroup of our respondents, as indicated by viral load measurement – a relevant biological marker associated with adherence status <a href="#pone.0000552-Nieuwkerk1">[27]</a>, <a href="#pone.0000552-Vrijens1">[31]</a>. This suggests that self-report of recent adherence was correlated with prior adherence in our respondents.</p>
<a id="article1.body1.sec4.p2" name="article1.body1.sec4.p2"></a><p>Our findings provide additional data in some areas where inconsistent or null findings have been reported in the literature. For example, a summary analysis of published studies on adherence <a href="#pone.0000552-Ammassari1">[10]</a> reported that age and race had been inconsistently associated with adherence in previously published multivariate analyses. We report associations between adherence and both age and race; our data agree with another recent report of higher adherence among older persons living with HIV infection <a href="#pone.0000552-Silverberg1">[32]</a>. The same summary of published literature <a href="#pone.0000552-Ammassari1">[10]</a> identified several factors which had not generally been associated with adherence in the published literature. These included risk factor for HIV infection, length of time on therapy, and number of antiretroviral drugs. Our analysis showed statistically significant associations with each of these factors, although for risk factor and time on therapy, our associations were marginally significant, especially in light of our large sample size.</p>
<a id="article1.body1.sec4.p3" name="article1.body1.sec4.p3"></a><p>Many investigators have reported lower adherence among persons with current substance use <a href="#pone.0000552-Lafeuillade1">[33]</a>–<a href="#pone.0000552-Arnsten1">[37]</a>. In contrast, Martini et al. <a href="#pone.0000552-Martini1">[38]</a> found that heroin, cocaine, and alcohol users were not more likely to report nonadherence. In our data, alcohol use and crack use, but not recent injection drug use, were associated with nonadherence.</p>
<a id="article1.body1.sec4.p4" name="article1.body1.sec4.p4"></a><p>Depression is a factor which has also been consistently associated with nonadherence <a href="#pone.0000552-Paterson1">[2]</a>, <a href="#pone.0000552-Carrieri1">[16]</a>, <a href="#pone.0000552-Arnsten1">[37]</a>, <a href="#pone.0000552-Gordillo1">[39]</a>–<a href="#pone.0000552-Chander1">[43]</a>. Although we did not have data on clinical diagnoses of depression, we included putative explanatory variables which might be associated with depression. For example, days of “feeling blue”, self-identified need for mental health services, and days of limited activity were considered in our modeling. Despite consistent evidence of the association between adherence and depression in the literature and a significant association between nonadherence and higher number of days feeling blue in our model, only 3% of our nonadherent respondents identified getting depressed as a main reason for missing doses.</p>
<a id="article1.body1.sec4.p5" name="article1.body1.sec4.p5"></a><p>Among respondents in our project, prescription of an unboosted – but not a boosted – PI-based regimen, was weakly associated with nonadherence. Weiser et al. <a href="#pone.0000552-Weiser2">[13]</a> reported no difference in adherence between patients prescribed NNRTI versus PI-based regimens. Other researchers have reported lower adherence among patients prescribed PI-based regimens <a href="#pone.0000552-Mannheimer1">[12]</a>, <a href="#pone.0000552-Maggiolo1">[14]</a>, <a href="#pone.0000552-Carrieri1">[16]</a>, while Glass et al. reported more nonadherence among patients prescribed a boosted PI-based regimen <a href="#pone.0000552-Glass1">[15]</a>. If adherence is truly higher in patients prescribed NNRTI-based regimens, it may be explained by a lower pill burden <a href="#pone.0000552-Maggiolo1">[14]</a>, <a href="#pone.0000552-Lafeuillade1">[33]</a>, <a href="#pone.0000552-Piliero1">[44]</a>. However, our analysis partially controlled for lower pill burden by controlling for the number of antiretroviral medications prescribed. Alternatively, higher adherence for those prescribed NNRTI regimens could be explained by fewer intolerable side effects. In our data, side effects were a commonly reported reason for missing doses among those who were nonadherent. Further, self-perception of body changes such as peripheral fat loss or central fat gain are associated with lower adherence <a href="#pone.0000552-Santos1">[45]</a>, and may be more common among those taking PI-based ARVT <a href="#pone.0000552-Lichtenstein1">[46]</a>.</p>
<a id="article1.body1.sec4.p6" name="article1.body1.sec4.p6"></a><p>Even if our finding of a marginal association of nonadherence with prescription of an unboosted PI-based regimen were confirmed by others, the clinical significance of this finding would be unclear. Recent findings <a href="#pone.0000552-Gross1">[47]</a> suggest that viral suppression may be maintained with less than 95% adherence for patients on boosted PI-based regimens. If this finding is substantiated in other settings, then future analyses of adherence and clinical guidelines may consider having regimen-specific thresholds to define acceptable adherence <a href="#pone.0000552-Smith1">[48]</a>.</p>
<a id="article1.body1.sec4.p7" name="article1.body1.sec4.p7"></a><p>Pill burdens for patients currently on ARVT are likely to be significantly lower now than were pill burdens at the time of our interviews <a href="#pone.0000552-Lafeuillade1">[33]</a>, <a href="#pone.0000552-Piliero1">[44]</a>. This is because of new formulations which include multiple drugs in a single pill or capsule, and regimens which require fewer prescribed doses per day.</p>
<a id="article1.body1.sec4.p8" name="article1.body1.sec4.p8"></a><p>Although the most commonly reported reason for missed ARVT doses was forgetting to take medications, the modal proportion of doses missed was 100%. The fact that nearly a quarter of non-adherent respondents took no medication during the 48 hour period suggests that, in many cases, doses are not missed sporadically. More prolonged periods of missed doses could represent “drug holiday” periods <a href="#pone.0000552-VanWijngaerden1">[49]</a>, periods in which patients ran out of medication, or periods when significant side effects or illness prevented taking any. Future work should attempt to characterize the reasons for these prolonged periods of missed doses.</p>
<a id="article1.body1.sec4.p9" name="article1.body1.sec4.p9"></a><p>Our study has some important limitations. As with any interview study, our data are subject to recall bias and social desirability bias <a href="#pone.0000552-Sackett1">[50]</a>. We believe asking about adherence in the 48 hours before the interview should minimize recall bias. Social desirability bias should lead to under-report of poor adherence, which has been recently confirmed <a href="#pone.0000552-Murri1">[18]</a>; this suggests that our data represent minimum estimates of nonadherence. However, social desirability bias has been reported not to be a major source of error in collecting self-reported adherence data <a href="#pone.0000552-Wagner1">[51]</a>. The persons recruited and interviewed in the SHAS project are not representative of all persons with HIV infection or AIDS in the project areas, or in the United States.</p>
<a id="article1.body1.sec4.p10" name="article1.body1.sec4.p10"></a><p>Further, there are important factors which are likely related to nonadherence which the SHAS interview did not collect, and therefore could not be included in our analysis. For example, we did not collect information on social support or isolation <a href="#pone.0000552-Altice1">[52]</a> (other than current living arrangements <a href="#pone.0000552-Gordillo1">[39]</a>), beliefs about prognosis or treatment efficacy <a href="#pone.0000552-Holmes1">[53]</a>, <a href="#pone.0000552-Nilsson1">[54]</a>, perceptions of body changes <a href="#pone.0000552-Santos1">[45]</a>, cognitive factors <a href="#pone.0000552-Wagner2">[55]</a>, <a href="#pone.0000552-Selnes1">[56]</a>, serostatus disclosure <a href="#pone.0000552-Stirratt1">[57]</a>, or life stress <a href="#pone.0000552-Nilsson1">[54]</a>, <a href="#pone.0000552-Bottonari1">[58]</a>.</p>
<a id="article1.body1.sec4.p11" name="article1.body1.sec4.p11"></a><p>These results have some relevance for clinicians and public health officials. Based on our findings and existing treatment guidelines <a href="#pone.0000552-Department1">[59]</a>, providers should consider that certain groups of patients may be especially likely to benefit from support and guidance around the importance of adherence and strategies for improving adherence. Our data, and the data of others, support referral to housing resources for homeless patients and referral to appropriate treatment for alcohol abuse, crack cocaine use, and mental health problems, either before or concurrently with prescription of antiretroviral medications. Some other factors associated with nonadherence among our respondents, such as race/ethnicity and age, are likely markers for other barriers that lead to poor adherence. Additional focused research is needed to determine the underlying challenges to adherence for these patients, and to develop interventions and resources to help physicians and patients overcome these challenges.</p>
<a id="article1.body1.sec4.p12" name="article1.body1.sec4.p12"></a><p>Adherence to antiretroviral medications also has important public health implications. Poor adherence to ARVT may be associated with the development of drug-resistant strains of HIV. Also, to the extent that ARVT lowers prevalent viral loads on a population basis, there should be a desirable impact on reducing the risk of HIV transmission. Poor adherence also compromises this potential population-level benefit of ARVT. Thus, adherence is a relevant behavior for targeting with interventions, and for monitoring as a part of future behavioral surveillance projects <a href="#pone.0000552-Gallagher1">[60]</a>. Although large-scale behavioral surveillance efforts are not designed to provide detailed clinical information about adherence and its consequences, and are subject to some important limitations, such systems offer the opportunity to measure important variables related to HIV care, including adherence, in an ongoing and systematic way.</p>
</div>





<div><a id="ack" name="ack" toc="ack" title="Acknowledgments"></a><h3>Acknowledgments</h3>
<a id="article1.back1.ack1.p1" name="article1.back1.ack1.p1"></a><p>The authors thank Eric Schwab, MS for his technical and editorial assistance, and Drs. Amy Lansky and Travis Sanchez for critical review. We thank April Smith for editorial assistance.</p>
<a id="article1.back1.ack1.p2" name="article1.back1.ack1.p2"></a><p>We also gratefully acknowledge the contributions of the SHAS Project principal investigators and project officers: Vjollca Berisha and Rick DeStephens, Arizona Department of Public Health; Arthur Davidson, Denver Health and Hospital Authority; Aaron Roome, Connecticut Department of Public Health; James Welch, Delaware Department of Public Health; Rebecca Grigg and Pam Lowell, Florida Department of Health; Jeffrey Lenox and Alan Fann, Emory University School of Medicine; Marcia Wolverton, Houston Department of Health and Human Services; Fran Eury, Illinois Department of Public Health; Jeni Mulqueen, Anthony Merriweather, and Gail Hansen, Kansas Department of Health and Environment; Amy Rock Wohl and Denise Johnston, Los Angeles County Department of Health; Ellen Caldeira, Maryland Department of Health and Mental Hygiene; Eve Mokotoff, Sha Juan Colbert, and Shanell McGoy, Michigan Department of Community Health; Richard Danila and Don Stiepan, Minnesota Department of Public Health; Sally D'Errico, New Jersey Department of Health; Mack Sewell, New Mexico Department of Public Health; Kathleen Brady, Philadelphia Department of Public Health; Terri Stephens, South Carolina Department of Health and Environmental Control; Sharon Melville and Sylvia Odem, Texas Department of Health; and Maria Courogen, Washington State Department of Health.</p>
<a id="article1.back1.ack1.p3" name="article1.back1.ack1.p3"></a><p>Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.</p>
</div><div class="contributions"><a id="authcontrib" name="authcontrib" toc="authcontrib" title="Author Contributions"></a><h3>Author Contributions</h3><p>Conceived and designed the experiments: PS MC EB AN. Performed the experiments: PS MC EB AN. Analyzed the data: PS GN JS. Contributed reagents/materials/analysis tools: MC GN EB JS AN. Wrote the paper: PS.</p></div><div><a id="references" name="references" toc="references" title="References"></a><h3>References</h3><ol class="references"><li><span class="label">1.
              </span><a name="pone.0000552-Carpenter1" id="pone.0000552-Carpenter1"></a>Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, et al.  (1998) Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA  280: 78–86.  <ul class="find" data-citedArticleID="960788" data-doi="10.1001/jama.280.1.78"><li><a href="http://dx.doi.org/10.1001/jama.280.1.78" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Antiretroviral+therapy+for+HIV+infection+in+1998%3A+updated+recommendations+of+the+International+AIDS+Society-USA+Panel." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Antiretroviral+therapy+for+HIV+infection+in+1998%3A+updated+recommendations+of+the+International+AIDS+Society-USA+Panel.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">2.
              </span><a name="pone.0000552-Paterson1" id="pone.0000552-Paterson1"></a>Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, et al.  (2000) Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med  133: 21–30.  <ul class="find" data-citedArticleID="960844" data-doi="10.7326/0003-4819-133-1-200007040-00004"><li><a href="http://dx.doi.org/10.7326/0003-4819-133-1-200007040-00004" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Adherence+to+protease+inhibitor+therapy+and+outcomes+in+patients+with+HIV+infection." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Adherence+to+protease+inhibitor+therapy+and+outcomes+in+patients+with+HIV+infection.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">3.
              </span><a name="pone.0000552-Hirsch1" id="pone.0000552-Hirsch1"></a>Hirsch MS, Conway B, D'Aquila RT, Johnson VA, Brun-Vezinet F, et al.  (1998) Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society–USA Panel. JAMA  279: 1984–1991.  <ul class="find" data-citedArticleID="960814" data-doi="10.1001/jama.279.24.1984"><li><a href="http://dx.doi.org/10.1001/jama.279.24.1984" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Antiretroviral+drug+resistance+testing+in+adults+with+HIV+infection%3A+implications+for+clinical+management.+International+AIDS+Society%26%23x2013%3BUSA+Panel." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Antiretroviral+drug+resistance+testing+in+adults+with+HIV+infection%3A+implications+for+clinical+management.+International+AIDS+Society%26%23x2013%3BUSA+Panel.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">4.
              </span><a name="pone.0000552-Wood1" id="pone.0000552-Wood1"></a>Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, et al.  (2004) The impact of adherence on CD4 cell count responses among HIV-infected patients. J Acquir Immune Defic Syndr  35: 261–268.  <ul class="find" data-citedArticleID="960888" data-doi="10.1097/00126334-200403010-00006"><li><a href="http://dx.doi.org/10.1097/00126334-200403010-00006" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=The+impact+of+adherence+on+CD4+cell+count+responses+among+HIV-infected+patients." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22The+impact+of+adherence+on+CD4+cell+count+responses+among+HIV-infected+patients.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">5.
              </span><a name="pone.0000552-Cohen1" id="pone.0000552-Cohen1"></a>Cohen M  Antiretroviral therapy to prevent sexual transmission of HIV. 13th Conference on Retroviruses and Opportunistic Infections, Denver Colorado, February 2006. Abstract 54.  <ul class="find-nolinks"></ul></li><li><span class="label">6.
              </span><a name="pone.0000552-Weiser1" id="pone.0000552-Weiser1"></a>Weiser B, Nachman S, Tropper P, Viscosi KH, Grimson R (1994) Quantitation of human immunodeficiency virus type 1 during pregnancy: relationship of viral titer to mother-to-child transmission and stability of viral load. Proc Natl Acad Sci USA  91: 8037–8041.  <ul class="find" data-citedArticleID="960884" data-doi="10.1073/pnas.91.17.8037"><li><a href="http://dx.doi.org/10.1073/pnas.91.17.8037" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Quantitation+of+human+immunodeficiency+virus+type+1+during+pregnancy%3A+relationship+of+viral+titer+to+mother-to-child+transmission+and+stability+of+viral+load." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Quantitation+of+human+immunodeficiency+virus+type+1+during+pregnancy%3A+relationship+of+viral+titer+to+mother-to-child+transmission+and+stability+of+viral+load.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">7.
              </span><a name="pone.0000552-Vlahov1" id="pone.0000552-Vlahov1"></a>Vlahov D, Safaien M, Lai S, Strathdee SA, Johnson L, et al.  (2001) Sexual and drug risk-related behaviours after initiating highly active antiretroviral therapy among injection drug users. AIDS  15: 2311–2316.  <ul class="find" data-citedArticleID="960872" data-doi="10.1097/00002030-200111230-00013"><li><a href="http://dx.doi.org/10.1097/00002030-200111230-00013" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Sexual+and+drug+risk-related+behaviours+after+initiating+highly+active+antiretroviral+therapy+among+injection+drug+users." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Sexual+and+drug+risk-related+behaviours+after+initiating+highly+active+antiretroviral+therapy+among+injection+drug+users.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">8.
              </span><a name="pone.0000552-Lansky1" id="pone.0000552-Lansky1"></a>Lansky A, Sullivan PS, Gallagher K, Fleming PL (2007) The HIV behavioral surveillance program in the US: a conceptual framework. Public Health Reports  122: Supp116–23.  <ul class="find" data-citedArticleID="960824"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=The+HIV+behavioral+surveillance+program+in+the+US%3A+a+conceptual+framework.&amp;auth=&amp;atitle=The+HIV+behavioral+surveillance+program+in+the+US%3A+a+conceptual+framework." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=The+HIV+behavioral+surveillance+program+in+the+US%3A+a+conceptual+framework." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22The+HIV+behavioral+surveillance+program+in+the+US%3A+a+conceptual+framework.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">9.
              </span><a name="pone.0000552-Reynolds1" id="pone.0000552-Reynolds1"></a>Reynolds NR (2004) Adherence to antiretroviral therapies: state of the science. Curr HIV Res  2: 207–214.  <ul class="find" data-citedArticleID="960848" data-doi="10.2174/1570162043351309"><li><a href="http://dx.doi.org/10.2174/1570162043351309" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Adherence+to+antiretroviral+therapies%3A+state+of+the+science." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Adherence+to+antiretroviral+therapies%3A+state+of+the+science.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">10.
              </span><a name="pone.0000552-Ammassari1" id="pone.0000552-Ammassari1"></a>Ammassari A, Trotta MP, Murri R, Castelli F, Narciso P, et al.  (2002) Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr  31: Suppl 3S123–S127.  <ul class="find" data-citedArticleID="960772" data-doi="10.1097/00126334-200212153-00007"><li><a href="http://dx.doi.org/10.1097/00126334-200212153-00007" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Correlates+and+predictors+of+adherence+to+highly+active+antiretroviral+therapy%3A+overview+of+published+literature." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Correlates+and+predictors+of+adherence+to+highly+active+antiretroviral+therapy%3A+overview+of+published+literature.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">11.
              </span><a name="pone.0000552-Trotta1" id="pone.0000552-Trotta1"></a>Trotta MP, Ammassari A, Cozzi-Lepri A, Zaccarelli M, Castelli F, et al.  (2003) Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens. AIDS  17: 1099–1102.  <ul class="find" data-citedArticleID="960868" data-doi="10.1097/00002030-200305020-00026"><li><a href="http://dx.doi.org/10.1097/00002030-200305020-00026" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Adherence+to+highly+active+antiretroviral+therapy+is+better+in+patients+receiving+non-nucleoside+reverse+transcriptase+inhibitor-containing+regimens+than+in+those+receiving+protease+inhibitor-containing+regimens." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Adherence+to+highly+active+antiretroviral+therapy+is+better+in+patients+receiving+non-nucleoside+reverse+transcriptase+inhibitor-containing+regimens+than+in+those+receiving+protease+inhibitor-containing+regimens.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">12.
              </span><a name="pone.0000552-Mannheimer1" id="pone.0000552-Mannheimer1"></a>Mannheimer S, Friedland G, Matts J, Child C, Chesney M (2002) The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis  34: 1115–1121.  <ul class="find" data-citedArticleID="960832" data-doi="10.1086/339074"><li><a href="http://dx.doi.org/10.1086/339074" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=The+consistency+of+adherence+to+antiretroviral+therapy+predicts+biologic+outcomes+for+human+immunodeficiency+virus-infected+persons+in+clinical+trials." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22The+consistency+of+adherence+to+antiretroviral+therapy+predicts+biologic+outcomes+for+human+immunodeficiency+virus-infected+persons+in+clinical+trials.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">13.
              </span><a name="pone.0000552-Weiser2" id="pone.0000552-Weiser2"></a>Weiser SD, Guzman D, Riley ED, Clark R, Bangsberg DR (2004) Higher rates of viral suppression with nonnucleoside reverse transcriptase inhibitors compared to single protease inhibitors are not explained by better adherence. HIV Clin Trials  5: 278–287.  <ul class="find" data-citedArticleID="960886" data-doi="10.1310/lnhd-k1r7-hqp5-hjcq"><li><a href="http://dx.doi.org/10.1310/lnhd-k1r7-hqp5-hjcq" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Higher+rates+of+viral+suppression+with+nonnucleoside+reverse+transcriptase+inhibitors+compared+to+single+protease+inhibitors+are+not+explained+by+better+adherence." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Higher+rates+of+viral+suppression+with+nonnucleoside+reverse+transcriptase+inhibitors+compared+to+single+protease+inhibitors+are+not+explained+by+better+adherence.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">14.
              </span><a name="pone.0000552-Maggiolo1" id="pone.0000552-Maggiolo1"></a>Maggiolo F, Ravasio L, Ripamonti D, Gregis G, Quinzan G, et al.  (2005) Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis  40: 158–163.  <ul class="find" data-citedArticleID="960828" data-doi="10.1086/426595"><li><a href="http://dx.doi.org/10.1086/426595" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Similar+adherence+rates+favor+different+virologic+outcomes+for+patients+treated+with+nonnucleoside+analogues+or+protease+inhibitors." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Similar+adherence+rates+favor+different+virologic+outcomes+for+patients+treated+with+nonnucleoside+analogues+or+protease+inhibitors.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">15.
              </span><a name="pone.0000552-Glass1" id="pone.0000552-Glass1"></a>Glass TR, De GS, Weber R, Vernazza PL, Rickenbach M, et al.  (2006) Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr  41: 385–392.  <ul class="find" data-citedArticleID="960808" data-doi="10.1097/01.qai.0000186371.95301.52"><li><a href="http://dx.doi.org/10.1097/01.qai.0000186371.95301.52" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Correlates+of+self-reported+nonadherence+to+antiretroviral+therapy+in+HIV-infected+patients%3A+the+Swiss+HIV+Cohort+Study." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Correlates+of+self-reported+nonadherence+to+antiretroviral+therapy+in+HIV-infected+patients%3A+the+Swiss+HIV+Cohort+Study.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">16.
              </span><a name="pone.0000552-Carrieri1" id="pone.0000552-Carrieri1"></a>Carrieri MP, Leport C, Protopopescu C, Cassuto JP, Bouvet E, et al.  (2006) Factors associated with nonadherence to highly active antiretroviral therapy: a 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase. J Acquir Immune Defic Syndr  41: 477–485.  <ul class="find" data-citedArticleID="960790" data-doi="10.1097/01.qai.0000186364.27587.0e"><li><a href="http://dx.doi.org/10.1097/01.qai.0000186364.27587.0e" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Factors+associated+with+nonadherence+to+highly+active+antiretroviral+therapy%3A+a+5-year+follow-up+analysis+with+correction+for+the+bias+induced+by+missing+data+in+the+treatment+maintenance+phase." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Factors+associated+with+nonadherence+to+highly+active+antiretroviral+therapy%3A+a+5-year+follow-up+analysis+with+correction+for+the+bias+induced+by+missing+data+in+the+treatment+maintenance+phase.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">17.
              </span><a name="pone.0000552-Bartlett1" id="pone.0000552-Bartlett1"></a>Bartlett JA (2002) Addressing the challenges of adherence. J Acquir Immune Defic Syndr  29: Suppl 1S2–10.  <ul class="find" data-citedArticleID="960780"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Addressing+the+challenges+of+adherence.&amp;auth=&amp;atitle=Addressing+the+challenges+of+adherence." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Addressing+the+challenges+of+adherence." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Addressing+the+challenges+of+adherence.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">18.
              </span><a name="pone.0000552-Murri1" id="pone.0000552-Murri1"></a>Murri R, Ammassari A, Trotta MP, De LA, Melzi S, et al.  (2004) Patient-reported and physician-estimated adherence to HAART: social and clinic center-related factors are associated with discordance. J Gen Intern Med  19: 1104–1110.  <ul class="find" data-citedArticleID="960838" data-doi="10.1111/j.1525-1497.2004.30248.x"><li><a href="http://dx.doi.org/10.1111/j.1525-1497.2004.30248.x" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Patient-reported+and+physician-estimated+adherence+to+HAART%3A+social+and+clinic+center-related+factors+are+associated+with+discordance." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Patient-reported+and+physician-estimated+adherence+to+HAART%3A+social+and+clinic+center-related+factors+are+associated+with+discordance.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">19.
              </span><a name="pone.0000552-Fairley1" id="pone.0000552-Fairley1"></a>Fairley CK, Permana A, Read TR (2005) Long-term utility of measuring adherence by self-report compared with pharmacy record in a routine clinic setting. HIV Med  6: 366–369.  <ul class="find" data-citedArticleID="960800" data-doi="10.1111/j.1468-1293.2005.00322.x"><li><a href="http://dx.doi.org/10.1111/j.1468-1293.2005.00322.x" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Long-term+utility+of+measuring+adherence+by+self-report+compared+with+pharmacy+record+in+a+routine+clinic+setting." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Long-term+utility+of+measuring+adherence+by+self-report+compared+with+pharmacy+record+in+a+routine+clinic+setting.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">20.
              </span><a name="pone.0000552-Walsh1" id="pone.0000552-Walsh1"></a>Walsh JC (1999) Adherence in clinical trials and in clinical practice. Antivir Ther  4: Suppl 349–54.  <ul class="find" data-citedArticleID="960880"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Adherence+in+clinical+trials+and+in+clinical+practice.&amp;auth=&amp;atitle=Adherence+in+clinical+trials+and+in+clinical+practice." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Adherence+in+clinical+trials+and+in+clinical+practice." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Adherence+in+clinical+trials+and+in+clinical+practice.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">21.
              </span><a name="pone.0000552-Kerr1" id="pone.0000552-Kerr1"></a>Kerr T, Walsh J, Lloyd-Smith E, Wood E (2005) Measuring adherence to highly active antiretroviral therapy: implications for research and practice. Curr HIV/AIDS Rep  2: 200–205.  <ul class="find" data-citedArticleID="960820" data-doi="10.1007/s11904-005-0017-3"><li><a href="http://dx.doi.org/10.1007/s11904-005-0017-3" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Measuring+adherence+to+highly+active+antiretroviral+therapy%3A+implications+for+research+and+practice." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Measuring+adherence+to+highly+active+antiretroviral+therapy%3A+implications+for+research+and+practice.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">22.
              </span><a name="pone.0000552-Chesney1" id="pone.0000552-Chesney1"></a>Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, et al.  (2000) Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee &amp; Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care  12: 255–266.  <ul class="find" data-citedArticleID="960794" data-doi="10.1080/09540120050042891"><li><a href="http://dx.doi.org/10.1080/09540120050042891" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Self-reported+adherence+to+antiretroviral+medications+among+participants+in+HIV+clinical+trials%3A+the+AACTG+adherence+instruments.+Patient+Care+Committee+%26amp%3B+Adherence+Working+Group+of+the+Outcomes+Committee+of+the+Adult+AIDS+Clinical+Trials+Group+%28AACTG%29." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Self-reported+adherence+to+antiretroviral+medications+among+participants+in+HIV+clinical+trials%3A+the+AACTG+adherence+instruments.+Patient+Care+Committee+%26amp%3B+Adherence+Working+Group+of+the+Outcomes+Committee+of+the+Adult+AIDS+Clinical+Trials+Group+%28AACTG%29.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">23.
              </span><a name="pone.0000552-Fletcher1" id="pone.0000552-Fletcher1"></a>Fletcher CV, Testa MA, Brundage RC, Chesney MA, Haubrich R, et al.  (2005) Four measures of antiretroviral medication adherence and virologic response in AIDS Clinical Trials Group Study 359. J Acquir Immune Defic Syndr  40: 301–306.  <ul class="find" data-citedArticleID="960804" data-doi="10.1097/01.qai.0000180078.53321.6a"><li><a href="http://dx.doi.org/10.1097/01.qai.0000180078.53321.6a" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Four+measures+of+antiretroviral+medication+adherence+and+virologic+response+in+AIDS+Clinical+Trials+Group+Study+359." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Four+measures+of+antiretroviral+medication+adherence+and+virologic+response+in+AIDS+Clinical+Trials+Group+Study+359.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">24.
              </span><a name="pone.0000552-Antinori1" id="pone.0000552-Antinori1"></a>Antinori A, Cozzi-Lepri A, Ammassari A, Trotta MP, Nauwelaers D, et al.  (2004) Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART. Antivir Ther  9: 291–296.  <ul class="find" data-citedArticleID="960776"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Relative+prognostic+value+of+self-reported+adherence+and+plasma+NNRTI%2FPI+concentrations+to+predict+virological+rebound+in+patients+initially+responding+to+HAART.&amp;auth=&amp;atitle=Relative+prognostic+value+of+self-reported+adherence+and+plasma+NNRTI%2FPI+concentrations+to+predict+virological+rebound+in+patients+initially+responding+to+HAART." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Relative+prognostic+value+of+self-reported+adherence+and+plasma+NNRTI%2FPI+concentrations+to+predict+virological+rebound+in+patients+initially+responding+to+HAART." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Relative+prognostic+value+of+self-reported+adherence+and+plasma+NNRTI%2FPI+concentrations+to+predict+virological+rebound+in+patients+initially+responding+to+HAART.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">25.
              </span><a name="pone.0000552-Walsh2" id="pone.0000552-Walsh2"></a>Walsh JC, Mandalia S, Gazzard BG (2002) Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS  16: 269–277.  <ul class="find" data-citedArticleID="960882" data-doi="10.1097/00002030-200201250-00017"><li><a href="http://dx.doi.org/10.1097/00002030-200201250-00017" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Responses+to+a+1+month+self-report+on+adherence+to+antiretroviral+therapy+are+consistent+with+electronic+data+and+virological+treatment+outcome." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Responses+to+a+1+month+self-report+on+adherence+to+antiretroviral+therapy+are+consistent+with+electronic+data+and+virological+treatment+outcome.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">26.
              </span><a name="pone.0000552-Simoni1" id="pone.0000552-Simoni1"></a>Simoni JM, Hurth A, Pearson C, Panatalone D, Merril J, et al.  (2006) Self-reported measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Behav  10: 199–212.  <ul class="find" data-citedArticleID="960858"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Self-reported+measures+of+antiretroviral+therapy+adherence%3A+a+review+with+recommendations+for+HIV+research+and+clinical+management.&amp;auth=&amp;atitle=Self-reported+measures+of+antiretroviral+therapy+adherence%3A+a+review+with+recommendations+for+HIV+research+and+clinical+management." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Self-reported+measures+of+antiretroviral+therapy+adherence%3A+a+review+with+recommendations+for+HIV+research+and+clinical+management." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Self-reported+measures+of+antiretroviral+therapy+adherence%3A+a+review+with+recommendations+for+HIV+research+and+clinical+management.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">27.
              </span><a name="pone.0000552-Nieuwkerk1" id="pone.0000552-Nieuwkerk1"></a>Nieuwkerk PT, Oort FJ (2005) Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: a meta-analysis. J Acquir Immune Defic Syndr  38: 445–448.  <ul class="find" data-citedArticleID="960840" data-doi="10.1097/01.qai.0000147522.34369.12"><li><a href="http://dx.doi.org/10.1097/01.qai.0000147522.34369.12" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Self-reported+adherence+to+antiretroviral+therapy+for+HIV-1+infection+and+virologic+treatment+response%3A+a+meta-analysis." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Self-reported+adherence+to+antiretroviral+therapy+for+HIV-1+infection+and+virologic+treatment+response%3A+a+meta-analysis.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">28.
              </span><a name="pone.0000552-Buehler1" id="pone.0000552-Buehler1"></a>Buehler JW, Diaz T, Hersh BS, Chu SY (1996) The supplement to HIV-AIDS Surveillance project: an approach for monitoring HIV risk behaviors. Public Health Rep  111: Suppl 1133–7.133–137.  <ul class="find" data-citedArticleID="960786"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=The+supplement+to+HIV-AIDS+Surveillance+project%3A+an+approach+for+monitoring+HIV+risk+behaviors.&amp;auth=&amp;atitle=The+supplement+to+HIV-AIDS+Surveillance+project%3A+an+approach+for+monitoring+HIV+risk+behaviors." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=The+supplement+to+HIV-AIDS+Surveillance+project%3A+an+approach+for+monitoring+HIV+risk+behaviors." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22The+supplement+to+HIV-AIDS+Surveillance+project%3A+an+approach+for+monitoring+HIV+risk+behaviors.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">29.
              </span><a name="pone.0000552-Maisto1" id="pone.0000552-Maisto1"></a>Maisto SA, Saitz R (2003) Alcohol use disorders: screening and diagnosis. Am J Addict  12: Suppl 1S12–S25.  <ul class="find" data-citedArticleID="960830" data-doi="10.1111/j.1521-0391.2003.tb00493.x"><li><a href="http://dx.doi.org/10.1111/j.1521-0391.2003.tb00493.x" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Alcohol+use+disorders%3A+screening+and+diagnosis." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Alcohol+use+disorders%3A+screening+and+diagnosis.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">30.
              </span><a name="pone.0000552-Farizo1" id="pone.0000552-Farizo1"></a>Farizo KM, Buehler JW, Chamberland ME, Whyte BM, Froelicher ES, et al.  (1992) Spectrum of disease in persons with human immunodeficiency virus infection in the United States. JAMA  267: 1798–1805.  <ul class="find" data-citedArticleID="960802" data-doi="10.1001/jama.267.13.1798"><li><a href="http://dx.doi.org/10.1001/jama.267.13.1798" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Spectrum+of+disease+in+persons+with+human+immunodeficiency+virus+infection+in+the+United+States." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Spectrum+of+disease+in+persons+with+human+immunodeficiency+virus+infection+in+the+United+States.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">31.
              </span><a name="pone.0000552-Vrijens1" id="pone.0000552-Vrijens1"></a>Vrijens B, Goetghebeur E, de Klerk E, Rode R, Mayer S, et al.  (2005) Modelling the association between adherence and viral load in HIV-infected patients. Stat Med  24: 2719–2731.  <ul class="find" data-citedArticleID="960874" data-doi="10.1002/sim.2130"><li><a href="http://dx.doi.org/10.1002/sim.2130" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Modelling+the+association+between+adherence+and+viral+load+in+HIV-infected+patients." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Modelling+the+association+between+adherence+and+viral+load+in+HIV-infected+patients.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">32.
              </span><a name="pone.0000552-Silverberg1" id="pone.0000552-Silverberg1"></a>Silverberg MJ, Leyden W, Horberg MA, DeLorenze GN, Klein D, et al.  (2007) Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med  167: 684–691.  <ul class="find" data-citedArticleID="960856" data-doi="10.1001/archinte.167.7.684"><li><a href="http://dx.doi.org/10.1001/archinte.167.7.684" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Older+age+and+the+response+to+and+tolerability+of+antiretroviral+therapy." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Older+age+and+the+response+to+and+tolerability+of+antiretroviral+therapy.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">33.
              </span><a name="pone.0000552-Lafeuillade1" id="pone.0000552-Lafeuillade1"></a>Lafeuillade A (2001) Factors affecting adherence and convenience in antiretroviral therapy. Int J STD AIDS  12: Suppl 418–24.  <ul class="find" data-citedArticleID="960822" data-doi="10.1258/0956462011924290"><li><a href="http://dx.doi.org/10.1258/0956462011924290" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Factors+affecting+adherence+and+convenience+in+antiretroviral+therapy." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Factors+affecting+adherence+and+convenience+in+antiretroviral+therapy.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">34.
              </span><a name="pone.0000552-Berg1" id="pone.0000552-Berg1"></a>Berg KM, Demas PA, Howard AA, Schoenbaum EE, Gourevitch MN, et al.  (2004) Gender differences in factors associated with adherence to antiretroviral therapy. J Gen Intern Med  19: 1111–1117.  <ul class="find" data-citedArticleID="960782" data-doi="10.1111/j.1525-1497.2004.30445.x"><li><a href="http://dx.doi.org/10.1111/j.1525-1497.2004.30445.x" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Gender+differences+in+factors+associated+with+adherence+to+antiretroviral+therapy." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Gender+differences+in+factors+associated+with+adherence+to+antiretroviral+therapy.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">35.
              </span><a name="pone.0000552-Moss1" id="pone.0000552-Moss1"></a>Moss AR, Hahn JA, Perry S, Charlebois ED, Guzman D (2004) Adherence to highly active antiretroviral therapy in the homeless population in San Francisco: a prospective study. Clin Infect Dis  39: 1190–1198.  <ul class="find" data-citedArticleID="960836" data-doi="10.1086/424008"><li><a href="http://dx.doi.org/10.1086/424008" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Adherence+to+highly+active+antiretroviral+therapy+in+the+homeless+population+in+San+Francisco%3A+a+prospective+study." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Adherence+to+highly+active+antiretroviral+therapy+in+the+homeless+population+in+San+Francisco%3A+a+prospective+study.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">36.
              </span><a name="pone.0000552-Howard1" id="pone.0000552-Howard1"></a>Howard AA, Arnsten JH, Lo Y, Vlahov D, Rich JD, et al.  (2002) A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS  16: 2175–2182.  <ul class="find" data-citedArticleID="960818" data-doi="10.1097/00002030-200211080-00010"><li><a href="http://dx.doi.org/10.1097/00002030-200211080-00010" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=A+prospective+study+of+adherence+and+viral+load+in+a+large+multi-center+cohort+of+HIV-infected+women." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22A+prospective+study+of+adherence+and+viral+load+in+a+large+multi-center+cohort+of+HIV-infected+women.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">37.
              </span><a name="pone.0000552-Arnsten1" id="pone.0000552-Arnsten1"></a>Arnsten JH, Demas PA, Grant RW, Gourevitch MN, Farzadegan H, et al.  (2002) Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med  17: 377–381.  <ul class="find" data-citedArticleID="960778" data-doi="10.1007/s11606-002-0044-3"><li><a href="http://dx.doi.org/10.1007/s11606-002-0044-3" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Impact+of+active+drug+use+on+antiretroviral+therapy+adherence+and+viral+suppression+in+HIV-infected+drug+users." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Impact+of+active+drug+use+on+antiretroviral+therapy+adherence+and+viral+suppression+in+HIV-infected+drug+users.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">38.
              </span><a name="pone.0000552-Martini1" id="pone.0000552-Martini1"></a>Martini M, Recchia E, Nasta P, Castanotto D, Chiaffarino F, et al.  (2004) Illicit drug use: can it predict adherence to antiretroviral therapy? Eur J Epidemiol  19: 585–587.  <ul class="find" data-citedArticleID="960834" data-doi="10.1023/b:ejep.0000032353.03967.ef"><li><a href="http://dx.doi.org/10.1023/b:ejep.0000032353.03967.ef" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Illicit+drug+use%3A+can+it+predict+adherence+to+antiretroviral+therapy%3F" target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Illicit+drug+use%3A+can+it+predict+adherence+to+antiretroviral+therapy%3F%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">39.
              </span><a name="pone.0000552-Gordillo1" id="pone.0000552-Gordillo1"></a>Gordillo V, del Amo J, Soriano V, Gonzalez-Lahoz J (1999) Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS  13: 1763–1769.  <ul class="find" data-citedArticleID="960810" data-doi="10.1097/00002030-199909100-00021"><li><a href="http://dx.doi.org/10.1097/00002030-199909100-00021" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Sociodemographic+and+psychological+variables+influencing+adherence+to+antiretroviral+therapy." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Sociodemographic+and+psychological+variables+influencing+adherence+to+antiretroviral+therapy.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">40.
              </span><a name="pone.0000552-Ammassari2" id="pone.0000552-Ammassari2"></a>Ammassari A, Antinori A, Aloisi MS, Trotta MP, Murri R, et al.  (2004) Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics  45: 394–402.  <ul class="find" data-citedArticleID="960774" data-doi="10.1176/appi.psy.45.5.394"><li><a href="http://dx.doi.org/10.1176/appi.psy.45.5.394" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Depressive+symptoms%2C+neurocognitive+impairment%2C+and+adherence+to+highly+active+antiretroviral+therapy+among+HIV-infected+persons." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Depressive+symptoms%2C+neurocognitive+impairment%2C+and+adherence+to+highly+active+antiretroviral+therapy+among+HIV-infected+persons.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">41.
              </span><a name="pone.0000552-Starace1" id="pone.0000552-Starace1"></a>Starace F, Ammassari A, Trotta MP, Murri R, De LP, et al.  (2002) Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr  31: Suppl 3S136–S139.  <ul class="find" data-citedArticleID="960864" data-doi="10.1097/00126334-200212153-00010"><li><a href="http://dx.doi.org/10.1097/00126334-200212153-00010" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Depression+is+a+risk+factor+for+suboptimal+adherence+to+highly+active+antiretroviral+therapy." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Depression+is+a+risk+factor+for+suboptimal+adherence+to+highly+active+antiretroviral+therapy.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">42.
              </span><a name="pone.0000552-Sledjeski1" id="pone.0000552-Sledjeski1"></a>Sledjeski EM, Delahanty DL, Bogart LM (2005) Incidence and impact of posttraumatic stress disorder and comorbid depression on adherence to HAART and CD4+ counts in people living with HIV. AIDS Patient Care STDS  19: 728–736.  <ul class="find" data-citedArticleID="960860" data-doi="10.1089/apc.2005.19.728"><li><a href="http://dx.doi.org/10.1089/apc.2005.19.728" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Incidence+and+impact+of+posttraumatic+stress+disorder+and+comorbid+depression+on+adherence+to+HAART+and+CD4%2B+counts+in+people+living+with+HIV." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Incidence+and+impact+of+posttraumatic+stress+disorder+and+comorbid+depression+on+adherence+to+HAART+and+CD4%2B+counts+in+people+living+with+HIV.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">43.
              </span><a name="pone.0000552-Chander1" id="pone.0000552-Chander1"></a>Chander G, Himelhoch S, Moore RD (2006) Substance abuse and psychiatric disorders in HIV-positive patients : epidemiology and impact on antiretroviral therapy. Drugs  66: 769–789.  <ul class="find" data-citedArticleID="960792" data-doi="10.2165/00003495-200666060-00004"><li><a href="http://dx.doi.org/10.2165/00003495-200666060-00004" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Substance+abuse+and+psychiatric+disorders+in+HIV-positive+patients+%3A+epidemiology+and+impact+on+antiretroviral+therapy." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Substance+abuse+and+psychiatric+disorders+in+HIV-positive+patients+%3A+epidemiology+and+impact+on+antiretroviral+therapy.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">44.
              </span><a name="pone.0000552-Piliero1" id="pone.0000552-Piliero1"></a>Piliero PJ, Colagreco JP (2003) Simplified regimens for treating HIV infection and AIDS. J Am Acad Nurse Pract  15: 305–312.  <ul class="find" data-citedArticleID="960846" data-doi="10.1111/j.1745-7599.2003.tb01313.x"><li><a href="http://dx.doi.org/10.1111/j.1745-7599.2003.tb01313.x" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Simplified+regimens+for+treating+HIV+infection+and+AIDS." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Simplified+regimens+for+treating+HIV+infection+and+AIDS.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">45.
              </span><a name="pone.0000552-Santos1" id="pone.0000552-Santos1"></a>Santos CP, Felipe YX, Braga PE, Ramos D, Lima RO, et al.  (2005) Self-perception of body changes in persons living with HIV/AIDS: prevalence and associated factors. AIDS  19: Suppl 4S14–S21.  <ul class="find" data-citedArticleID="960852" data-doi="10.1097/01.aids.0000191485.92285.c7"><li><a href="http://dx.doi.org/10.1097/01.aids.0000191485.92285.c7" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Self-perception+of+body+changes+in+persons+living+with+HIV%2FAIDS%3A+prevalence+and+associated+factors." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Self-perception+of+body+changes+in+persons+living+with+HIV%2FAIDS%3A+prevalence+and+associated+factors.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">46.
              </span><a name="pone.0000552-Lichtenstein1" id="pone.0000552-Lichtenstein1"></a>Lichtenstein KA (2005) Redefining lipodystrophy syndrome: risks and impact on clinical decision making. J Acquir Immune Defic Syndr  39: 395–400.  <ul class="find" data-citedArticleID="960826" data-doi="10.1097/01.qai.0000167478.28051.3a"><li><a href="http://dx.doi.org/10.1097/01.qai.0000167478.28051.3a" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Redefining+lipodystrophy+syndrome%3A+risks+and+impact+on+clinical+decision+making." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Redefining+lipodystrophy+syndrome%3A+risks+and+impact+on+clinical+decision+making.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">47.
              </span><a name="pone.0000552-Gross1" id="pone.0000552-Gross1"></a>Gross R, Yip B, Wood E, Bangsberg D, Justice A, Montaner J, et al. Boosted PIs are more forgiving of suboptimal adherence than non-boosted PIs or NNRTIs.   Thirteenth Conference on Retroviruses and Opportunistic Infections, Denver, abstract 533, 2006.  <ul class="find-nolinks"></ul></li><li><span class="label">48.
              </span><a name="pone.0000552-Smith1" id="pone.0000552-Smith1"></a>Smith RJ (2006) Adherence to antiretroviral HIV drugs: how many doses can you miss before resistance emerges? Proc Biol Sci  273: 617–624.  <ul class="find" data-citedArticleID="960862" data-doi="10.1098/rspb.2005.3352"><li><a href="http://dx.doi.org/10.1098/rspb.2005.3352" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Adherence+to+antiretroviral+HIV+drugs%3A+how+many+doses+can+you+miss+before+resistance+emerges%3F" target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Adherence+to+antiretroviral+HIV+drugs%3A+how+many+doses+can+you+miss+before+resistance+emerges%3F%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">49.
              </span><a name="pone.0000552-VanWijngaerden1" id="pone.0000552-VanWijngaerden1"></a>Van Wijngaerden E, De Saar V, DeGraeve V, Vandamme AM, Van Vaerenbergh K, et al.  (2002) Nonadherence to highly active antiretroviral therapy: clinically relevant patient categorization based on electronic event monitoring. AIDS Res Hum Retroviruses  18: 327–330.  <ul class="find" data-citedArticleID="960870" data-doi="10.1089/088922202753519098"><li><a href="http://dx.doi.org/10.1089/088922202753519098" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Nonadherence+to+highly+active+antiretroviral+therapy%3A+clinically+relevant+patient+categorization+based+on+electronic+event+monitoring." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Nonadherence+to+highly+active+antiretroviral+therapy%3A+clinically+relevant+patient+categorization+based+on+electronic+event+monitoring.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">50.
              </span><a name="pone.0000552-Sackett1" id="pone.0000552-Sackett1"></a>Sackett DL (1979) Bias in analytic research. J Chronic Dis  32: 51–63.  <ul class="find" data-citedArticleID="960850" data-doi="10.1016/0021-9681(79)90012-2"><li><a href="http://dx.doi.org/10.1016/0021-9681(79)90012-2" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Bias+in+analytic+research." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Bias+in+analytic+research.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">51.
              </span><a name="pone.0000552-Wagner1" id="pone.0000552-Wagner1"></a>Wagner G, Miller LG (2004) Is the influence of social desirability on patients' self-reported adherence overrated? J Acquir Immune Defic Syndr  35: 203–204.  <ul class="find" data-citedArticleID="960876" data-doi="10.1097/00126334-200402010-00016"><li><a href="http://dx.doi.org/10.1097/00126334-200402010-00016" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Is+the+influence+of+social+desirability+on+patients%27+self-reported+adherence+overrated%3F" target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Is+the+influence+of+social+desirability+on+patients%27+self-reported+adherence+overrated%3F%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">52.
              </span><a name="pone.0000552-Altice1" id="pone.0000552-Altice1"></a>Altice FL, Mostashari F, Friedland GH (2001) Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr  28: 47–58.  <ul class="find" data-citedArticleID="960770" data-doi="10.1097/00126334-200109010-00008"><li><a href="http://dx.doi.org/10.1097/00126334-200109010-00008" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Trust+and+the+acceptance+of+and+adherence+to+antiretroviral+therapy." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Trust+and+the+acceptance+of+and+adherence+to+antiretroviral+therapy.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">53.
              </span><a name="pone.0000552-Holmes1" id="pone.0000552-Holmes1"></a>Holmes WC, Pace JL (2002) HIV-seropositive individuals' optimistic beliefs about prognosis and relation to medication and safe sex adherence. J Gen Intern Med  17: 677–683.  <ul class="find" data-citedArticleID="960816" data-doi="10.1046/j.1525-1497.2002.00746.x"><li><a href="http://dx.doi.org/10.1046/j.1525-1497.2002.00746.x" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=HIV-seropositive+individuals%27+optimistic+beliefs+about+prognosis+and+relation+to+medication+and+safe+sex+adherence." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22HIV-seropositive+individuals%27+optimistic+beliefs+about+prognosis+and+relation+to+medication+and+safe+sex+adherence.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">54.
              </span><a name="pone.0000552-Nilsson1" id="pone.0000552-Nilsson1"></a>Nilsson SL, Diamond PM, Ross MW, Williams M, Bratt G (2006) Baseline predictors of three types of antiretroviral therapy (ART) adherence: a 2-year follow-up. AIDS Care  18: 246–253.  <ul class="find" data-citedArticleID="960842" data-doi="10.1080/09540120500456631a"><li><a href="http://dx.doi.org/10.1080/09540120500456631a" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Baseline+predictors+of+three+types+of+antiretroviral+therapy+%28ART%29+adherence%3A+a+2-year+follow-up." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Baseline+predictors+of+three+types+of+antiretroviral+therapy+%28ART%29+adherence%3A+a+2-year+follow-up.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">55.
              </span><a name="pone.0000552-Wagner2" id="pone.0000552-Wagner2"></a>Wagner GJ (2002) Predictors of antiretroviral adherence as measured by self-report, electronic monitoring, and medication diaries. AIDS Patient Care STDS  16: 599–608.  <ul class="find" data-citedArticleID="960878" data-doi="10.1089/108729102761882134"><li><a href="http://dx.doi.org/10.1089/108729102761882134" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Predictors+of+antiretroviral+adherence+as+measured+by+self-report%2C+electronic+monitoring%2C+and+medication+diaries." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Predictors+of+antiretroviral+adherence+as+measured+by+self-report%2C+electronic+monitoring%2C+and+medication+diaries.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">56.
              </span><a name="pone.0000552-Selnes1" id="pone.0000552-Selnes1"></a>Selnes OA (2002) Neurocognitive aspects of medication adherence in HIV infection. J Acquir Immune Defic Syndr  31: Suppl 3S132–S135.  <ul class="find" data-citedArticleID="960854" data-doi="10.1097/00126334-200212153-00009"><li><a href="http://dx.doi.org/10.1097/00126334-200212153-00009" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Neurocognitive+aspects+of+medication+adherence+in+HIV+infection." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Neurocognitive+aspects+of+medication+adherence+in+HIV+infection.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">57.
              </span><a name="pone.0000552-Stirratt1" id="pone.0000552-Stirratt1"></a>Stirratt MJ, Remien RH, Smith A, Copeland OQ, Dolezal C, et al.  (2006) The role of HIV serostatus disclosure in antiretroviral medication adherence. AIDS Behav  10: 483–493.  <ul class="find" data-citedArticleID="960866" data-doi="10.1007/s10461-006-9106-6"><li><a href="http://dx.doi.org/10.1007/s10461-006-9106-6" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=The+role+of+HIV+serostatus+disclosure+in+antiretroviral+medication+adherence." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22The+role+of+HIV+serostatus+disclosure+in+antiretroviral+medication+adherence.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">58.
              </span><a name="pone.0000552-Bottonari1" id="pone.0000552-Bottonari1"></a>Bottonari KA, Roberts JE, Ciesla JA, Hewitt RG (2005) Life stress and adherence to antiretroviral therapy among HIV-positive individuals: a preliminary investigation. AIDS Patient Care STDS  19: 719–727.  <ul class="find" data-citedArticleID="960784" data-doi="10.1089/apc.2005.19.719"><li><a href="http://dx.doi.org/10.1089/apc.2005.19.719" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Life+stress+and+adherence+to+antiretroviral+therapy+among+HIV-positive+individuals%3A+a+preliminary+investigation." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Life+stress+and+adherence+to+antiretroviral+therapy+among+HIV-positive+individuals%3A+a+preliminary+investigation.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">59.
              </span><a name="pone.0000552-Department1" id="pone.0000552-Department1"></a>Department of Health and Humans Services (2006) Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents: adherence to potent antiretroviral therapy.   Available at: <a href="http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL_AdherenceSup.pdf">http://aidsinfo.nih.gov/contentfiles/Adu​ltandAdolescentGL_AdherenceSup.pdf</a>. Last accessed: May 31, 2007.  <ul class="find-nolinks"></ul></li><li><span class="label">60.
              </span><a name="pone.0000552-Gallagher1" id="pone.0000552-Gallagher1"></a>Gallagher KM, Sullivan PS, Lansky A, Onorato IM (2007) Behavioral surveillance among persons risk for HIV infection in the United States: The National HIV Behavioral Surveillance System. Public Health Reports  122: Supp 132–38.  <ul class="find" data-citedArticleID="960806"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Behavioral+surveillance+among+persons+risk+for+HIV+infection+in+the+United+States%3A+The+National+HIV+Behavioral+Surveillance+System.&amp;auth=&amp;atitle=Behavioral+surveillance+among+persons+risk+for+HIV+infection+in+the+United+States%3A+The+National+HIV+Behavioral+Surveillance+System." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Behavioral+surveillance+among+persons+risk+for+HIV+infection+in+the+United+States%3A+The+National+HIV+Behavioral+Surveillance+System." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Behavioral+surveillance+among+persons+risk+for+HIV+infection+in+the+United+States%3A+The+National+HIV+Behavioral+Surveillance+System.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li></ol></div>

  </div>

      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000552.XML" value="102087"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000552.PDF" value="103783"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000552.t001.PNG_L" value="184246"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000552.t001.PNG_M" value="91450"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000552.t001.PNG_S" value="8342"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000552.t001.TIF" value="901372"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000552.t001.PNG_I" value="94674"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000552.t002.PNG_L" value="214398"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000552.t002.PNG_M" value="84338"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000552.t002.PNG_S" value="9534"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000552.t002.TIF" value="1068662"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000552.t002.PNG_I" value="119956"/>

</div>
<div class="sidebar">

  <div class="article-actions cf">
      <div class="download">
        <span class="btn"><a href="/article/fetchObject.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0000552&amp;representation=PDF" title="Download" target="_blank">Download PDF</a></span>
      </div>
      <div class="btn-reveal dropdown">
        <div class="dropdown-icon">
          <span class="btn">&nbsp;</span>
        </div>

        <div class="content">
          <ul class="bullet">
            <li><a href="/article/citationList.action?articleURI=info%3Adoi%2F10.1371%2Fjournal.pone.0000552" title="Download citations">Citation</a></li>
            <li><a href="/article/fetchObjectAttachment.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0000552&amp;representation=XML" title="Download article XML">XML</a></li>
          </ul>
        </div>
      </div> <!-- end btn-reveal dropdown-->


    <div class="btn-reveal flt-l">
        <span class="btn">Print</span>
        <div class="content">
            <ul class="bullet">
                <li id="print-article"><a href="#" onclick="if(typeof(_gaq) != 'undefined'){ _gaq.push(['_trackEvent','Article', 'Print', 'Click']); } window.print(); return false;" title="Print Article">Print article</a></li>
                <li>
                  <a href="https://www.odysseypress.com/onlinehost/reprint_order.php?type=A&page=0&journal=7&doi=10.1371/journal.pone.0000552&volume=&issue=&title=Patient and Regimen Characteristics Associated with Self-Reported Nonadherence to Antiretroviral Therapy&author_name=Patrick%20S.%20Sullivan%2C%20Michael%20L.%20Campsmith%2C%20Glenn%20V.%20Nakamura%2C%20Elin%20B.%20Begley%2C%20Jeffrey%20Schulden%2C%20Allyn%20K.%20Nakashima&start_page=1&end_page=6" title="Odyssey Press">EzReprint</a>
                </li>
            </ul>
        </div>
    </div>

    <div class="btn-reveal flt-r">
        <span class="btn">Share</span>
        <div class="content">
            <ul class="social">
                <li><a href="http://www.reddit.com/submit?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000552" target="_blank" title="Submit to Reddit"><img src="/images/icon.reddit.16.png" width="16" height="16" alt="Reddit">Reddit</a></li>

                <li><a href="https://plus.google.com/share?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000552" target="_blank" title="Share on Google+"><img src="/images/icon.gplus.16.png" width="16" height="16" alt="Google+">Google+</a></li>

                <li><a href="http://www.stumbleupon.com/submit?url=http%3A%2F%2Fwww.plosone.org%2Farticle%2Finfo%253Adoi%252F10.1371%252Fjournal.pone.0000552" target="_blank" title="Add to StumbleUpon"><img src="/images/icon.stumble.16.png" width="16" height="16" alt="StumbleUpon">StumbleUpon</a></li>

                <li><a href="http://www.facebook.com/share.php?u=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000552&amp;t=Patient%20and%20Regimen%20Characteristics%20Associated%20with%20Self-Reported%20Nonadherence%20to%20Antiretroviral%20Therapy" target="_blank" title="Share on Facebook"><img src="/images/icon.fb.16.png" width="16" height="16" alt="Facebook">Facebook</a></li>

                <li><a href="http://www.linkedin.com/shareArticle?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000552&title=Patient%20and%20Regimen%20Characteristics%20Associated%20with%20Self-Reported%20Nonadherence%20to%20Antiretroviral%20Therapy&summary=Checkout%20this%20article%20I%20found%20at%20PLOS" target="_blank" title="Add to LinkedIn"><img src="/images/icon.linkedin.16.png" width="16" height="16" alt="Mendeley">LinkedIn</a></li>

                <li><a href="http://www.citeulike.org/posturl?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000552&amp;title=Patient%20and%20Regimen%20Characteristics%20Associated%20with%20Self-Reported%20Nonadherence%20to%20Antiretroviral%20Therapy" target="_blank" title="Add to CiteULike"><img src="/images/icon.cul.16.png" width="16" height="16" alt="CiteULike">CiteULike</a></li>

                <li><a href="http://www.mendeley.com/import/?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000552" target="_blank" title="Add to Mendeley"><img src="/images/icon.mendeley.16.png" width="16" height="16" alt="Mendeley">Mendeley</a></li>

                <li><a href="https://www.pubchase.com/library?add_aid=10.1371%2Fjournal.pone.0000552&amp;source=plos" target="_blank" title="Add to PubChase"><img src="/images/icon.pc.16.png" width="16" height="16" alt="PubChase">PubChase</a></li>


                <script type="text/javascript">
                    // replace tweet with one that's pre-shortened to 140 chars
                    function truncateTweetText() {
                        var twtTitle = 'Patient and Regimen Characteristics Associated with Self-Reported Nonadherence to Antiretroviral Therapy';
                        var twtUrl = 'http://dx.plos.org/10.1371/journal.pone.0000552';
                        // all URLs posted to twitter get auto-shortened to 20 chars.
                        var maxLength = 140 - (20 + 1);
                        // truncate the title to include space for twtTag and ellipsis (here, 10 = tag length + space + ellipsis)
                        if (twtTitle.length > maxLength) { twtTitle = twtTitle.substr(0, (maxLength - 10)) + '...'; }
                        // set the href to use the shortened tweet
                        $('#twitter-share-link').prop('href', 'http://twitter.com/intent/tweet?text=' + encodeURIComponent('#PLOSONE: ' + twtTitle + ' ' + twtUrl));
                    }
                </script>
                <li><a href="http://twitter.com/intent/tweet?text=#PLOSONE%3A%20Patient%20and%20Regimen%20Characteristics%20Associated%20with%20Self-Reported%20Nonadherence%20to%20Antiretroviral%20Therapy http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000552" onclick="truncateTweetText();" target="_blank" title="Share on Twitter" id="twitter-share-link"><img src="/images/icon.twtr.16.png" width="16" height="16" alt="Twitter">Twitter</a></li>

                <li><a href="/article/email/info%3Adoi%2F10.1371%2Fjournal.pone.0000552" title="Email this article"><img src="/images/icon.email.16.png" width="16" height="16" alt="Email">Email</a></li>
            </ul>
        </div>
    </div><!--end btn-reveal flt-r-->
</div><!-- end article-actions-->

<!-- begin Crossmark -->

<a id="open-crossmark" href="#" style="margin-top: -28px; display:block"><img style="border: 0; display: none;
 padding: 10px 0 18px 0;"  id="crossmark-icon" src="/images/logo-crossmark-bw.png" /></a>
<div id="crossmark-dialog" style="display: none;" title="">
    <!-- the external CrossMark data is loaded inside this iframe -->
    <iframe id="crossmark-dialog-frame" frameborder="0"></iframe>
</div>

<!-- end crossmark -->


<div class="block" id="subject-area-sidebar-block">
    <div class="header">
        <h3>Subject Areas</h3><div title="More information" id="subject-area-sidebar-block-help-icon"><img align="right"
                                                                                                           alt="info" src="/images/button_info.png"/><div id="subject-area-sidebar-block-help"><img align="right"
                                                                                                                                                                                                    src="/images/button_info.png"/><p>
        <b>We want your feedback.</b> Do these subject areas make sense for this article? If not, click the flag
        next to the incorrect subject area and we will review it. Thanks for your help!
    </p></div></div>
    </div>


    <ul id="subject-area-sidebar-list">



















          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22AIDS%22" title="Search for articles in the subject area:'AIDS'"><div class="flagText">AIDS</div></a>
              <div data-categoryid="47633" data-articleid="23942"
                   data-categoryname="AIDS"
                   class="flagImage" title="Flag 'AIDS' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Alcohols%22" title="Search for articles in the subject area:'Alcohols'"><div class="flagText">Alcohols</div></a>
              <div data-categoryid="18367" data-articleid="23942"
                   data-categoryname="Alcohols"
                   class="flagImage" title="Flag 'Alcohols' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Antiretroviral+therapy%22" title="Search for articles in the subject area:'Antiretroviral therapy'"><div class="flagText">Antiretroviral therapy</div></a>
              <div data-categoryid="32515" data-articleid="23942"
                   data-categoryname="Antiretroviral therapy"
                   class="flagImage" title="Flag 'Antiretroviral therapy' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Antiretrovirals%22" title="Search for articles in the subject area:'Antiretrovirals'"><div class="flagText">Antiretrovirals</div></a>
              <div data-categoryid="42987" data-articleid="23942"
                   data-categoryname="Antiretrovirals"
                   class="flagImage" title="Flag 'Antiretrovirals' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Drug+therapy%22" title="Search for articles in the subject area:'Drug therapy'"><div class="flagText">Drug therapy</div></a>
              <div data-categoryid="18461" data-articleid="23942"
                   data-categoryname="Drug therapy"
                   class="flagImage" title="Flag 'Drug therapy' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22HIV%22" title="Search for articles in the subject area:'HIV'"><div class="flagText">HIV</div></a>
              <div data-categoryid="42663" data-articleid="23942"
                   data-categoryname="HIV"
                   class="flagImage" title="Flag 'HIV' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22HIV+infections%22" title="Search for articles in the subject area:'HIV infections'"><div class="flagText">HIV infections</div></a>
              <div data-categoryid="47749" data-articleid="23942"
                   data-categoryname="HIV infections"
                   class="flagImage" title="Flag 'HIV infections' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Viral+load%22" title="Search for articles in the subject area:'Viral load'"><div class="flagText">Viral load</div></a>
              <div data-categoryid="21755" data-articleid="23942"
                   data-categoryname="Viral load"
                   class="flagImage" title="Flag 'Viral load' as inappropriate"></div>
          </li>
    </ul>
</div>

<div class="ad">
    <div class="title">Advertisement</div>






  <iframe id='a0852f54' name='a0852f54'
    src='http://ads.plos.org/www/delivery/afr.php?zoneid=381&amp;cb=6590'
    frameborder='0' scrolling='no' width='160' height='600'>
    <a href='http://ads.plos.org/www/delivery/ck.php?n=a0852f54&amp;cb=9621'
      target='_top'><img src='http://ads.plos.org/www/delivery/avw.php?zoneid=381&amp;cb=3438&amp;n=a0852f54'
      border='0' alt=''/>
    </a>
  </iframe>



</div>

<div id="twitter-alm-timeline" class="twitter-alm-timeline"></div>


</div><!-- sidebar -->
    </div>
  </div>
</div>
<script src="http://wl.figshare.com/static/p_widget.js" type="text/javascript"></script><div id="pageftr">
  <div class="ftr-cols cf">
    <div class="col col-1">
      <img src="/images/logo-plos-footer.png" alt="PLOS Logo" class="logo" />
      <p><a href="/static/releaseNotes">Ambra 2.9.16</a> Managed Colocation provided <br />by <a href="http://www.isc.org/">Internet Systems Consortium</a>.<p>
      <div class="nav nav-aux">
        <a href="/static/privacy">Privacy Policy</a> |
        <a href="/static/terms">Terms of Use</a> |
        <a href="http://www.plos.org/advertise/">Advertise</a> |
        <a href="http://www.plos.org/about/media-inquiries/">Media Inquiries</a>
      </div>
    </div>
    <div class="col col-2">
      <p><a href="http://www.plos.org/publications/journals/">Publications</a></p>
      <div class="nav">
        <ul>
          <li><a href="http://www.plosbiology.org">PLOS Biology</a></li>
          <li><a href="http://www.plosmedicine.org">PLOS Medicine</a></li>
          <li><a href="http://www.ploscompbiol.org">PLOS Computational Biology</a></li>
          <li><a href="http://currents.plos.org">PLOS Currents</a></li>
          <li><a href="http://www.plosgenetics.org">PLOS Genetics</a></li>
          <li><a href="http://www.plospathogens.org">PLOS Pathogens</a></li>
          <li><a href="http://www.plosone.org">PLOS ONE</a></li>
          <li><a href="http://www.plosntds.org">PLOS Neglected Tropical Diseases</a></li>
        </ul>
      </div>
    </div>
    <div class="col col-3">
      <div class="nav">
        <p><a href="http://www.plos.org">plos.org</a></p>
        <p><a href="http://blogs.plos.org">Blogs</a></p>
        <p><a href="http://www.ploscollections.org">Collections</a></p>
        <p><a href="/feedback/new">Send us feedback</a></p>

        <p>California (US) corporation #C2354500, based in San Francisco</p>
      </div>
    </div>
  </div>
</div><!-- pageftr -->

</div><!-- end page-wrap, this div is in header.ftl -->
<script type="text/javascript" src="/javascript/jquery-1.8.1-min.js?v=Tm7VCOzZz3lE03ghpkS6SWkHbyI"></script>
<script type="text/javascript" src="/javascript/ga-min.js?v=lNQ4gt8QcPDatjsdOFl_FGpPhLY"></script>
<script type="text/javascript" src="/javascript/jquery.hoverIntent-min.js?v=mRiGNYY9cIXxVb8u0K_MdW7hHnc"></script>
<script type="text/javascript" src="/javascript/jquery.placeholder-min.js?v=21Pn56Ur9h1N4K4VZDa0nqI3Pxo"></script>
<script type="text/javascript" src="/javascript/jquery.jsonp-2.4.0-min.js?v=lqTpzoHfSq3I5Ygo01qq5WankEo"></script>
<script type="text/javascript" src="/javascript/jquery-ui-1.9.2.custom-min.js?v=raSSlfNO0YsV5uUpAKmTB9n5VTc"></script>
<script type="text/javascript" src="/javascript/jquery.tooltip-min.js?v=cw+6Smh+mdryIA25xvqIvHMrnZM"></script>
<script type="text/javascript" src="/javascript/jquery.uniform-min.js?v=kYUAnX6W2W_2fK3RIuQ2m_YFG9U"></script>
<script type="text/javascript" src="/javascript/jquery.pjax-min.js?v=939kLBjL5_YKbx71T1RHjYaD4l8"></script>
<script type="text/javascript" src="/javascript/imagesloaded-min.js?v=XeuAp8Gc3mvQUo+wZCSF8ttPwvw"></script>
<script type="text/javascript" src="/javascript/figviewer-min.js?v=yPUa0sUQ_iHkI+IRv2i9bjyZJFo"></script>
<script type="text/javascript" src="/javascript/global-min.js?v=0Q3PwjeaWtXYDnqIsQvnL_ou0qs"></script>
<script type="text/javascript" src="/javascript/jquery.touchswipe-min.js?v=huaek_e6HqTduvCNAN91dJolTyw"></script>
<script type="text/javascript" src="/javascript/jquery.base64-min.js?v=VwV1zeVqKZj5FCAdlK0q5NRxbBg"></script>
<script type="text/javascript" src="/javascript/alm-min.js?v=Y5gm6B0b4Kx2YHNObNrgEeBgXlY"></script>
<script type="text/javascript" src="/javascript/taxonomy-browser-min.js?v=vBVMuDMYkGJCXIUxLe35GoyiJNw"></script>
<script type="text/javascript" src="/javascript/jquery.filterize-min.js?v=j0ZKVnHyk2nhFy8eIuNJkp7xaM0"></script>
<script type="text/javascript" src="/javascript/plosone-min.js?v=TK4H4arL_XBSwwJq+K1N3kqYfAI"></script>
<script type="text/javascript" src="/javascript/twitter-min.js?v=xKgcxLsQFXy+at1ao1NVke8nFlM"></script>
<script type="text/javascript" src="/javascript/crossmark.1.4-min.js?v=3FO4k0SjwTaGNnKGNSqthar1080"></script>
<script type="text/javascript">
  var _sf_async_config={uid:16579,domain:"plosone.org"};
  (function(){
    function loadChartbeat() {
      window._sf_endpt=(new Date()).getTime();
      var e = document.createElement('script');
      e.setAttribute('language', 'javascript');
      e.setAttribute('type', 'text/javascript');
      e.setAttribute('src',
          (("https:" == document.location.protocol) ? "https://a248.e.akamai.net/chartbeat.download.akamai.com/102508/" : "http://static.chartbeat.com/") +
              "js/chartbeat.js");
      document.body.appendChild(e);
    }
    var oldonload = window.onload;
    window.onload = (typeof window.onload != 'function') ?
        loadChartbeat : function() { oldonload(); loadChartbeat(); };
  })();
</script>
<!-- <script type="application/javascript" src="http://crossmark.crossref.org/javascripts/v1.3/crossmark.min.js"></script> -->

</body>
</html>
